Table of Contents

• Trial overview
• Who is being studied
• What is being measured
• Trial design and treatment groups
• Why this study matters

Trial overview

The available clinical trial for GXV813 is a Phase 2 interventional study called STAR-1.^[1] It is authorised and includes 142 participants.^[1]

The study is designed to assess the safety, tolerability, and treatment response of GXV813 in people with schizophrenia.^[1] The trial compares GXV813 with placebo to see whether the study drug improves symptoms.^[1]

Who is being studied

This study focuses on hospitalized adults with schizophrenia who are having an acute episode.^[1] The trial summary says the participants are adult inpatients diagnosed according to DSM-5 criteria.^[1]

In simple terms, this means the study is looking at people who are currently in the hospital and whose symptoms are active enough to need close care.^[1]

What is being measured

The main endpoint is the change from baseline in PANSS total score at 6 weeks.^[1] Baseline means the starting point before treatment begins.^[1]

PANSS stands for Positive and Negative Symptom Scale, which is a rating tool used to measure schizophrenia symptoms.^[1] A change in this score helps researchers see whether symptoms improve, worsen, or stay the same over time.^[1]

Trial design and treatment groups

The study is interventional, which means researchers assign the treatment rather than just observing what happens.^[1] The interventions listed are GXV813 given orally and placebo in hard gelatin capsule form.^[1]

Placebo is a comparison treatment that does not contain the active study drug.^[1] Using placebo helps researchers judge whether any symptom change is due to GXV813 rather than chance or other factors.^[1]

Why this study matters

Schizophrenia can affect both positive symptoms, such as hallucinations or delusions, and negative symptoms, such as low motivation or reduced speech.^[1] This trial is important because it focuses on both types of symptoms in a hospital setting where people may need close monitoring.^[1]

Because the study is in Phase 2, it is part of the process of learning whether GXV813 may help people with schizophrenia and how it performs in a larger patient group.^[1]

Table of Contents

• Trial overview
• Who can participate
• Study design and treatment groups
• What is being measured
• Trial status and size

Trial overview

One clinical trial is studying NBI-1117570 in adults with schizophrenia who need inpatient hospitalization.^[1] The trial is designed to see whether the study drug can improve behavioral and psychological symptoms of schizophrenia compared with placebo.^[1]

This is an interventional study, which means researchers give a study treatment and then measure the results.^[1] The trial is in Phase 2, so it is focused on learning more about how well the treatment may work while still collecting study information on safety and effects.^[1]

Who can participate

The trial is for inpatient adults with schizophrenia.^[1] Inpatient means the person is staying in a hospital setting for treatment, not just coming for a short visit.^[1]

The source data does not give more detail about other entry rules, such as exact age limits, symptom levels, or past treatment history.^[1]

Study design and treatment groups

The trial compares NBI-1117570 with placebo.^[1] A placebo is a look-alike treatment that does not contain the active study drug, and it helps researchers compare outcomes in a fair way.^[1]

The intervention list shows oral use for NBI-1117570 and a placebo for NBI-1117570.^[1] The study data do not provide more detail about the schedule of treatment or how long participants are followed.^[1]

What is being measured

The main outcome is the change from baseline in the Positive and Negative Syndrome Scale, or PANSS, total score.^[1] Baseline means the starting measurement before treatment begins.^[1]

PANSS is a score used to measure how severe schizophrenia symptoms are.^[1] In simple terms, the researchers are checking whether symptoms improve after treatment and whether the change is greater than with placebo.^[1]

Trial status and size

The trial status is Authorised, which means it has permission to start.^[1] The planned enrollment is 169 participants.^[1]

Because only one trial is listed in the source data, the current research picture for NBI-1117570 is limited to this Phase 2 study in hospitalized adults with schizophrenia.^[1]

Table of Contents

• Trial overview
• Who can take part
• Study design and treatment
• What the study measures
• Trial phase and status
• Why this research matters

Trial overview

The available trial data describe one interventional study of ROPINIROLE in healthy volunteers.^[1] The study is designed to test whether a single oral dose changes metacognition and resting-state functional brain connectivity.^[1]

The trial title and summary show that the main focus is not a disease treatment study, but a mechanistic study of how ROPINIROLE may affect self-monitoring and brain network activity in people without a known illness.^[1]

Who can take part

The target population is healthy adults, described in the trial as healthy volunteers.^[1] The study does not list a disease group, so it is aimed at understanding the drug’s effect in people without the condition being studied.^[1]

The enrollment goal is 20 participants, which means this is a small study.^[1] Small studies like this are often used to explore a question before larger studies are done.^[1]

Study design and treatment

This is an interventional trial, meaning the researchers give a study treatment and then measure the effect.^[1] The intervention includes placebo and ROPINIROLE 1 mg given by mouth as a single dose.^[1]

Placebo is a look-alike treatment with no active study drug, and it is used to compare results fairly.^[1] The trial compares ROPINIROLE with placebo to see whether the drug changes confidence, accuracy, and brain connectivity.^[1]

What the study measures

The primary endpoint is the within-participant change in metacognitive efficiency, also called the M-ratio, under ROPINIROLE versus placebo.^[1] This is measured from confidence ratings during cognitive testing and uses a signal-detection-theoretic framework, which helps separate self-judgment from task performance.^[1]

The study uses a modified version of the Rey Auditory-Verbal Learning Test, which is a memory task that asks people to learn and recall words.^[1] Researchers use trial-by-trial accuracy and confidence ratings to see whether confidence matches actual performance.^[1]

The summary also says the study will look at metacognitive bias, meaning the gap between confidence and actual performance, and Goodman–Kruskal Gamma correlation, which shows how well confidence separates correct answers from errors.^[1] The brief summary states that the researchers want to know whether ROPINIROLE changes confidence without changing basic cognitive performance.^[1]

Trial phase and status

The trial is listed as Phase 4 and has the status Authorised.^[1] In the trial record, Phase 4 is linked with a product that already has marketing authorization and has been shown to be safe in humans.^[1]

Even though the product is already authorised, this study is still important because it asks a new research question about brain function and self-evaluation in healthy people.^[1]

Why this research matters

The trial summary explains that the researchers want to understand how dopaminergic stimulation may affect insight into one’s own performance.^[1] In simple terms, they are studying whether ROPINIROLE can make people more or less overconfident about their answers.^[1]

The study is also meant to help explain brain systems involved in self-awareness and unawareness of neurological disturbances, which is sometimes called anosognosia.^[1] The data suggest that findings from healthy volunteers may help guide future research on people who have problems with insight into their condition.^[1]

Table of contents

• Trial overview
• Who the trial is for
• What is being studied
• Trial phase and design
• Outcomes being measured
• Treatments in the study
• Patient-focused summary

Trial overview

The available clinical trial is an interventional study called the PREDICT clinical trial, and it is authorised.^[1] It studies depressive disorder and looks at whether a pre-emptive pharmacogenetic strategy can improve the choice of antidepressant treatment after a previous treatment has failed.^[1]

The trial includes 240 participants and is in Phase 3.^[1] Its brief summary says the study compares a personalized medicine approach with standard clinical practice in people who are starting a new therapy after treatment failure.^[1]

Who the trial is for

This trial is for patients with depressive disorder who need a new antidepressant after their prior therapy did not work well enough.^[1] The source data does not give more detailed entry rules such as age limits or exact lab requirements.^[1]

• Target population: people with depressive disorder.^[1]

• Treatment situation: starting a new antidepressant after prior treatment failure.^[1]

• Study setting: patients are being evaluated in a real treatment decision context, not just for one fixed drug choice.^[1]

What is being studied

The main question is whether a pre-emptive pharmacogenetic strategy can help choose antidepressants better than usual care.^[1] Pre-emptive means the testing is done before the treatment decision is made, and pharmacogenetic means the study uses gene-related information to guide medicine selection.^[1]

The study also uses demographic, clinical, and concomitant medication data when making treatment decisions.^[1] Concomitant medication means other medicines a patient is already taking at the same time.^[1]

Although the trial is about treatment selection rather than one single drug, TRIMIPRAMINE MALEATE is included among the treatment options listed in the study data.^[1]

Trial phase and design

This is a Phase 3 clinical trial.^[1] Phase 3 trials usually test how well a strategy works in a larger group and help compare it with routine care.^[1]

The study is interventional, which means researchers actively assign or guide the treatment approach being tested.^[1] In this case, the intervention is the personalized selection strategy, not only a single medicine.^[1]

Outcomes being measured

The main outcome is symptom remission, meaning the depression symptoms improve a lot or may no longer be present.^[1] The trial measures this by looking at changes in depression severity scores after the new antidepressant treatment begins.^[1]

• PHQ-9: a patient questionnaire used to measure depression severity.^[1]

• MADRS: a clinician-rated scale used to measure how severe depression symptoms are.^[1]

The outcome is assessed after initiation of the new antidepressant treatment following failure of the prior therapy at study entry.^[1]

Treatments in the study

The intervention list includes many antidepressants and related medicines, such as escitalopram, duloxetine, fluvoxamine, sertraline, desvenlafaxine, fluoxetine, vortioxetine, venlafaxine, amitriptyline hydrochloride, citalopram, bupropion, mirtazapine, valproxan, quetiapine, and TRIMIPRAMINE MALEATE.^[1]

These medicines are part of the treatment selection process being compared in the trial, so the study is focused on choosing the right antidepressant strategy rather than testing only one product by itself.^[1]

• Antidepressant choices: the trial includes several medicines so researchers can compare how well the selection strategy works in practice.^[1]

• Personalized selection: the study uses gene-related and clinical information to help decide which treatment may work best.^[1]

Patient-focused summary

For patients, this trial is about finding a better way to choose antidepressant treatment after one treatment has not helped enough.^[1] The study asks whether adding genetic testing and other patient information can improve the chance of remission compared with usual care.^[1]

The source data does not report results yet, so the main focus is on the study goal, the patient group, and the outcomes being measured.^[1]

Table of contents

• Clinical trials overview
• Alcohol use disorder studies
• Asthma study
• Main endpoints and what they mean
• Who may take part
• Trial design and study status

Clinical trials overview

Current studies of LY3537031 are testing it in two different conditions: alcohol use disorder and uncontrolled moderate to severe asthma.^[1][2][3] These are interventional studies, which means researchers give a study treatment and compare results with placebo.^[1][2][3]

All three trials are listed as Authorised.^[1][2][3] Two studies are in Phase 3, and one study is in Phase 2.^[1][2][3]

Alcohol use disorder studies

Two Phase 3 trials are studying LY3537031 in people with alcohol use disorder, including one study in participants with moderate-to-severe alcohol use disorder.^[1][2] The planned enrollment is 949 participants in one study and 1,090 participants in the other.^[1][2]

The main goal in both alcohol studies is to show that at least one dose level is better than placebo for at least one of the dual primary endpoints.^[1][2] In simple terms, this means the researchers want to see whether LY3537031 helps people do better than placebo on the main results the study is designed to measure.^[1][2]

These studies also include a second period for responders, meaning people who improved in Period 1.^[1][2] In Period 2, the trial checks whether LY3537031 can help maintain a general reduction in alcohol consumption over time.^[1][2]

One alcohol study lists the primary outcome as behaviors associated with alcohol use disorder, measured by the Timeline Followback Method (TLFB).^[2] TLFB is a structured way to track drinking behavior over a set period.^[2]

Asthma study

One Phase 2 trial is studying LY3537031 in adult participants with uncontrolled moderate to severe asthma.^[3] The study plans to enroll 538 participants.^[3]

The main purpose of this trial is to compare LY3537031 with placebo and see whether it reduces severe asthma exacerbations.^[3] An asthma exacerbation is a worsening of asthma symptoms, often called a flare-up or attack.^[3]

The primary outcome is the annualized asthma exacerbation rate over 52 weeks of treatment, measured from baseline to Week 52.^[3] This means the study counts how often severe asthma flare-ups happen during the treatment period.^[3]

Main endpoints and what they mean

A primary endpoint is the main result a clinical trial uses to decide whether the treatment is working.^[1][2][3] In the alcohol studies, the endpoints focus on alcohol-related behavior and reduced alcohol consumption.^[1][2]

In the asthma study, the main endpoint is the rate of severe flare-ups during one year of treatment.^[3] This helps researchers understand whether the study treatment can lower the number of asthma worsening events over time.^[3]

Who may take part

The alcohol use disorder trials are for participants with alcohol use disorder, and one of them specifically names moderate-to-severe alcohol use disorder.^[1][2] The asthma trial is for adult participants with uncontrolled moderate to severe asthma.^[3]

Each study has its own entry rules, but the trial records show the main target groups clearly.^[1][2][3] The studies are designed for people who have the condition being tested, not for the general population.^[1][2][3]

Trial design and study status

All three studies are interventional and compare LY3537031 with placebo.^[1][2][3] The alcohol studies use a multi-period design, with an early period to test response and a later period to see whether benefits last in responders.^[1][2]

The asthma study follows participants for 52 weeks, which gives researchers a longer view of asthma control during treatment.^[3] All studies are currently marked as authorised, which means they have been approved to move forward in the trial process.^[1][2][3]

Table of Contents

• Overview of [18F]MC225 Clinical Research
• Understanding P-glycoprotein Function
• Clinical Trial in Treatment-Resistant Depression
• Clinical Trial in Neurodegenerative Diseases
• How [18F]MC225 is Administered
• What the Trials are Measuring

Overview of [18F]MC225 Clinical Research

[18F]MC225 is a radiotracer being investigated in clinical trials for its ability to measure P-glycoprotein (P-gp) function in the brain using PET/CT imaging. Currently, two Phase 2 clinical trials have been authorized to study this imaging agent in different patient populations^[1][2].

The chemical name of [18F]MC225 is 5-(1-(2-[18F]fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen. This compound is labeled with fluorine-18, a radioactive isotope that allows it to be detected by PET scanners^[2].

These clinical trials represent important research efforts to understand how P-glycoprotein activity may be altered in various brain disorders. The trials are investigating both psychiatric conditions, specifically treatment-resistant depression, and neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment^[1][2].

Understanding P-glycoprotein Function

P-glycoprotein is a protein that functions as a transporter in cell membranes throughout the body, with particularly important roles at the blood-brain barrier. This barrier is a protective system that controls which substances can enter brain tissue from the bloodstream.

P-gp acts as an efflux pump, meaning it actively pumps certain substances out of cells and prevents them from entering the brain. This mechanism serves several important functions:

• Protection: P-gp helps protect the brain from potentially toxic compounds by preventing their entry into brain tissue
• Drug transport: P-gp can affect how medications reach the brain, which may influence treatment effectiveness
• Disease involvement: Changes in P-gp function have been linked to various neurological and psychiatric conditions

Understanding P-gp activity in different disease states may help explain why some patients respond to treatments while others do not, and could lead to better therapeutic approaches.

Clinical Trial in Treatment-Resistant Depression

The first authorized trial (2023-508303-20-01) is investigating the role of P-glycoprotein in treatment-resistant depression (TRD). This Phase 2 interventional study plans to enroll 44 participants^[1].

The primary aim of this study is to assess the involvement of P-gp in TRD by comparing P-gp activity between two groups of patients:

• Subjects with treatment-resistant depression: Patients whose depression has not responded adequately to standard antidepressant treatments
• Subjects with treatment-responsive depression (DRESP): Patients whose depression has responded well to antidepressant medications

The study uses [18F]MC225 PET/CT imaging to measure P-gp activity in the brain. The hypothesis behind this research is that differences in P-gp function may explain why some patients respond to antidepressant medications while others do not^[1].

If P-gp is more active in patients with treatment-resistant depression, it might be pumping antidepressant medications out of the brain before they can have their therapeutic effect. This would represent an important mechanism of treatment resistance and could point to new therapeutic strategies.

Clinical Trial in Neurodegenerative Diseases

The second authorized trial (2024-518865-85-00) is evaluating [18F]MC225 to measure P-glycoprotein function in patients with neurodegenerative diseases. This Phase 2 study plans to enroll 30 participants^[2].

The trial is investigating three related neurodegenerative conditions:

• Alzheimer’s disease: A progressive brain disorder that causes memory loss and cognitive decline, characterized by the buildup of abnormal proteins in the brain
• Mild Cognitive Impairment (MCI): A condition involving noticeable decline in cognitive abilities that is greater than expected for age but not severe enough to interfere significantly with daily activities; MCI may progress to Alzheimer’s disease
• Parkinson’s disease: A progressive disorder affecting movement and coordination, caused by loss of nerve cells in specific brain regions

Changes in P-glycoprotein function have been observed in neurodegenerative diseases and may contribute to disease progression. P-gp alterations could affect the accumulation of toxic proteins in the brain or influence how medications used to treat these conditions reach their targets^[2].

This trial aims to characterize P-gp function across these different neurodegenerative conditions, which may help researchers understand disease mechanisms and develop better treatments.

How [18F]MC225 is Administered

[18F]MC225 is administered as an intravenous injection, meaning it is injected directly into a vein. The dose used in the clinical trial for neurodegenerative diseases is 400 MBq (megabecquerel), which is a unit measuring radioactivity^[2].

The administration process typically involves the following steps:

• Preparation: The radiotracer is prepared in a specialized facility and must be used within a short time frame due to the radioactive decay of fluorine-18
• Injection: The [18F]MC225 solution is injected intravenously, usually into an arm vein
• Distribution: After injection, the radiotracer circulates through the bloodstream and crosses into the brain
• Imaging: PET/CT scanning is performed to detect where the radiotracer accumulates in the brain

The amount of radiation exposure from [18F]MC225 is comparable to other diagnostic nuclear medicine procedures and is considered safe for research purposes when appropriate safety protocols are followed.

What the Trials are Measuring

Both clinical trials use specialized imaging measurements to assess P-glycoprotein function in the brain. These measurements provide quantitative data about how [18F]MC225 is distributed in brain tissue.

The trial in treatment-resistant depression is measuring P-gp activity by assessing [18F]MC225 standardized uptake value (SUV) and volume distribution (VD) in the whole brain. SUV is a measurement that indicates how much radiotracer has accumulated in brain tissue, while volume distribution describes how the tracer spreads throughout the brain^[1].

The trial in neurodegenerative diseases is measuring regional PET tracer uptake and influx values of [18F]MC225. This approach examines specific brain regions rather than the whole brain, which may reveal regional differences in P-gp function that are relevant to different neurodegenerative diseases^[2].

Key measurements being assessed include:

• Uptake values: How much [18F]MC225 accumulates in different brain regions, which reflects P-gp activity (higher uptake may indicate lower P-gp activity, as less tracer is being pumped out)
• Influx values: The rate at which [18F]MC225 enters brain tissue from the bloodstream
• Regional patterns: Differences in tracer distribution across various brain areas, which may correlate with disease-specific patterns
• Comparison between groups: Differences in measurements between patients with different conditions or treatment responses

These measurements will help researchers understand whether P-glycoprotein function is altered in treatment-resistant depression and neurodegenerative diseases, and whether these alterations follow specific patterns that could be clinically meaningful.

The data collected from these Phase 2 trials will be important for determining whether [18F]MC225 PET imaging can serve as a useful tool for understanding disease mechanisms, predicting treatment responses, or monitoring disease progression in these conditions.

Table of Contents

• Trial overview
• Conditions being studied
• How the trials are designed
• What the trials measure
• Who can participate
• Trial status and size
• Key points for patients

Trial overview

The listed studies are all Phase 3 trials, which means they are testing Xanomeline Tartrate in larger groups to learn more about benefit and safety.^[1] Most of the studies are interventional, meaning researchers give a study treatment and compare results with placebo or another study group.^[1]

The trials focus on several brain and mental health conditions, including schizophrenia, bipolar I mania, agitation related to Alzheimer’s disease, psychosis related to Alzheimer’s disease, and mild to moderate Alzheimer’s disease with cognitive impairment.^[1]

Conditions being studied

Schizophrenia is being studied in adults and also in adolescents aged 13 to 17 years.^[1] One schizophrenia study is for people with inadequately controlled symptoms, and another is a rollover study that follows people who finished an earlier trial.^[1]

Bipolar-I disorder studies focus on manic episodes, including mania with mixed features, which means mania together with some depression symptoms.^[1] One study looks at people taking lithium, valproate, or lamotrigine, which are mood-stabilizing medicines already used for bipolar disorder.^[1]

Several studies also look at Alzheimer’s disease-related symptoms, including agitation, psychosis, and cognitive impairment in mild to moderate disease.^[1] Agitation means restlessness or distress, while psychosis means symptoms such as hallucinations or delusions.^[1]

How the trials are designed

Some studies compare Xanomeline Tartrate with placebo, which is a dummy treatment with no active medicine.^[1] This helps researchers see whether changes are likely due to the study treatment rather than chance.^[1]

Several trials test Xanomeline Tartrate as a single treatment, while others test it as an add-on treatment.^[1] The Alzheimer’s disease agitation studies and the bipolar I mania study with mood stabilizers are examples of add-on or combination research.^[1]

There are also open-label extension studies, which means participants and researchers know what treatment is being given and the main goal is to watch long-term safety and tolerability.^[1]

What the trials measure

The studies use different rating tools depending on the condition being treated.^[1] For schizophrenia, the PANSS total score is used to measure symptom change, and one study in Alzheimer’s disease psychosis uses the NPI-C hallucinations and delusions score.^[1]

For mania in bipolar I disorder, the main measure is the YMRS, which tracks manic symptoms.^[1] For agitation in Alzheimer’s disease, the trials use the CMAI-IPA total score to measure change in agitation.^[1]

The cognitive impairment studies in Alzheimer’s disease use ADAS-Cog11 for thinking skills and CIBIC+ for global functioning, which means the person’s overall condition and day-to-day change.^[1] Long-term safety studies mainly track treatment-emergent adverse events, which are side effects or medical problems that appear after treatment starts.^[1]

Who can participate

Based on the trial data, the main groups are adults with schizophrenia, adults with bipolar I disorder, and adults with Alzheimer’s disease-related symptoms.^[1] One study also includes adolescents aged 13 to 17 years with schizophrenia.^[1]

Some studies are limited to people with a specific symptom pattern, such as mania with mixed features or psychosis associated with Alzheimer’s disease.^[1] Other studies include people who have already completed a previous trial or those already taking mood stabilizers for bipolar I disorder.^[1]

Trial status and size

Most of the listed trials are Authorised, which means they are approved to run in the source data provided.^[1] Two schizophrenia studies are marked Completed, and one study in schizophrenia is marked Withdrawn.^[1]

The enrollment numbers range from 166 participants in the adolescent schizophrenia study to 602 participants in the open-label extension study for agitation in Alzheimer’s disease.^[1] These larger numbers help researchers collect more information about both benefit and safety over time.^[1]

Key points for patients

• Most studies are trying to see whether Xanomeline Tartrate improves symptoms better than placebo.^[1]

• The main conditions are schizophrenia, bipolar I mania, and Alzheimer’s disease-related agitation, psychosis, and cognitive impairment.^[1]

• Some studies look at short-term symptom change, while others focus on long-term safety and tolerability.^[1]

• Different rating scales are used depending on the condition, such as PANSS, YMRS, CMAI-IPA, NPI-C, ADAS-Cog11, and CIBIC+.^[1]

• The studies include adults, and one trial includes teenagers with schizophrenia.^[1]

Table of Contents

• Trial overview
• Who participated
• What was studied
• Main outcomes
• Study design and phase
• What the study tracked

Trial overview

The clinical trial with YOHIMBINE HYDROCHLORIDE was titled “Understanding the Neurobiology of Pharmacologically-induced Acute Stress on Ethical Decisions” and was listed as completed.^[1] It was an interventional study, which means researchers gave study treatments and then measured the effects.^[1]

Who participated

The trial was designed to study the effects of yohimbine and/or hydrocortisone on moral judgment in military personnel.^[1] The study enrolled 100 people.^[1]

What was studied

The study aimed to observe how YOHIMBINE HYDROCHLORIDE and related study treatments affected moral judgment during a situation meant to mimic an acute stress response in humans.^[1] In simple terms, the researchers wanted to see whether stress-related treatment changed how people made ethical choices.^[1]

The listed interventions were cellulose microcrystalline, YOCORAL 5 mg tabletten, and Hydrocortison Teva 10 mg, all given orally in the trial record.^[1] The source data does not provide more detail about how these were compared beyond their listing in the study.^[1]

Main outcomes

The primary outcomes focused on the number of utilitarian, deontological, and compromise choices in a behavioral task measuring moral judgment.^[1] These are different ways people may decide what to do in a difficult ethical situation.^[1]

The trial also measured the number of violations in rationality when making moral decisions.^[1] This means the researchers looked for choices that did not follow expected logical patterns in the task.^[1]

Study design and phase

This was a Phase 3 trial.^[1] Phase 3 studies are later-stage trials that usually test how well an intervention works in a larger group of people.^[1]

The study was completed, so the planned research activities were finished.^[1] The available data does not include results, so this article focuses on what the trial planned to measure rather than on final findings.^[1]

What the study tracked

The trial tracked how people responded in a moral decision task under a stress-like condition.^[1] The key idea was to see whether study treatment changed the balance between rule-based decisions, outcome-based decisions, and middle-ground choices.^[1]

Because the source data is limited to one study, the clinical trial picture for YOHIMBINE HYDROCHLORIDE is narrow and specific.^[1] It centers on stress, ethics, and decision-making in military personnel rather than on a broad range of diseases.^[1]

Table of Contents

• Overview of the trials
• Main studies that include Vortioxetine
• Who can take part
• What the trials measure
• Trial phases and status
• What the results may mean

Overview of the trials

The trial data show that Vortioxetine is being studied in the setting of depression care, not as a stand-alone drug description. These trials look at how treatment plans work for people with major depressive disorder, other depressive disorders, or depression that is already in remission (meaning symptoms have improved a lot).^[1][2][3]

All three trials listed are Phase 3 studies, which are later-stage trials that test treatment strategies in larger groups of people.^[1][2][3] The studies are authorised and focus on real treatment questions such as symptom improvement, treatment failure, and stopping antidepressants safely.^[1][2][3]

Main studies that include Vortioxetine

One study is a randomised, controlled trial in people with major depressive disorder who had a first-time treatment failure on their first-line treatment.^[1] It compares a six-week intensified pharmacological treatment with treatment as usual, and Vortioxetine is one of the medicines used in the intensified treatment arm.^[1]

This study measures whether symptoms improve by week 6, using the MADRS total score as the main outcome.^[1] MADRS is a scale used to rate how severe depression symptoms are.^[1]

A second study looks at the safe discontinuation of antidepressants in people with currently remitted depressive disorders.^[2] In this trial, Vortioxetine appears as Brintellix oral drops, which is the product name listed in the source data.^[2] The study compares hyperbolic tapering with linear tapering, which are two different ways to lower a medicine dose over time.^[2]

The third study is the PREDICT clinical trial, which tests a pharmacogenetic strategy for choosing antidepressants in people with depressive disorder after prior treatment failure.^[3] Vortioxetine is listed as Vortioxetina Kern Pharma among many possible antidepressant options in this trial.^[3] The goal is to see whether using genetic and clinical data can improve the choice of the next antidepressant treatment.^[3]

Who can take part

The first trial includes people with major depressive disorder who had a first-time treatment failure on first-line treatment.^[1] This means the first treatment did not work well enough, so a different strategy is being tested.^[1]

The second trial includes adults with currently remitted depressive disorders.^[2] These are people whose depression is currently controlled well enough that the study can test whether antidepressants can be stopped safely.^[2]

The PREDICT trial includes people with depressive disorder who are starting a new antidepressant after prior therapy failure.^[3] This trial uses information such as demographic data, clinical history, and other medicines to help guide treatment choice.^[3]

What the trials measure

The first study measures the change in depression symptoms from baseline to six weeks, using the MADRS score.^[1] It also compares the results between the intensified treatment group and the usual care group, including a subgroup of people with first-time treatment failure.^[1]

The discontinuation study measures the proportion of participants who fail to stop the antidepressant or restart it during the 16 weeks after stopping.^[2] In simple terms, the trial checks whether people can follow the planned dose reduction and stay off the medicine without needing to go back on it.^[2]

The PREDICT trial measures symptom remission using changes in PHQ-9 and MADRS scores after a new antidepressant is started.^[3] Symptom remission means depression symptoms improve enough that they are much less of a problem.^[3]

Trial phases and status

All three studies are in Phase 3, which usually means the treatment approach is being tested in a larger and more practical patient group.^[1][2][3] This phase is often used to confirm whether a strategy works well and to compare it with another standard approach.^[1][2][3]

Each trial in the source data is marked Authorised, meaning it has been approved to proceed in the setting described by the record.^[1][2][3] The planned enrollment ranges from 150 to 453 participants across the studies.^[1][2][3]

What the results may mean

Taken together, these trials show that Vortioxetine is being studied within broader depression treatment strategies rather than as a single isolated question.^[1][2][3] The studies look at different patient groups: people with active depression, people with treatment failure, and people whose depression is already in remission.^[1][2][3]

They also use different outcome measures, such as depression rating scales and the ability to stop antidepressants successfully.^[1][2][3] This helps researchers compare treatment approaches and understand which strategy may work best for different types of patients.^[1][2][3]

Table of Contents

• Trial overview
• Who is being studied
• What the trial measures
• Trial design and phase
• Key patient terms

Trial overview

This clinical trial is studying Vortioxetine Hydrobromide in people with a recent diagnosis of schizophrenia.^[1] The study is described as an interventional trial, which means researchers give a study treatment and then measure the results.^[1]

The trial title says it is looking at an already authorized drug for other conditions in people with schizophrenia.^[1] The study is authorised and has 37 planned participants.^[1]

Who is being studied

The trial focuses on people with schizophrenia and schizophrenia spectrum disorders.^[1] The brief summary also says the study is for people with early psychosis, which means the early stage of a psychotic illness.^[1]

Psychosis is a mental state where a person may have trouble telling what is real.^[1] In this study, the main concern is not only the illness itself, but also cognitive problems linked with early psychosis.^[1]

What the trial measures

The main outcome is cognitive functioning improvement, measured by the change in BACS App scores.^[1] Cognitive functioning means thinking skills such as memory, attention, and planning.^[1]

BACS stands for Brief Assessment of Cognition in Schizophrenia, a test used to check thinking skills in people with schizophrenia.^[1] The summary says the score is tracked from baseline to Week 24, with additional time points at Week 26 and Week 50.^[1]

The study uses a Composite Z-score, which means several test results are combined into one overall score.^[1] This helps researchers see whether thinking skills improve over time.^[1]

Trial design and phase

This is a Phase 4 trial.^[1] Phase 4 studies usually look at an already authorized treatment in a real-world setting or for another use.^[1]

The intervention list includes several antipsychotic drugs, along with Vortioxetine Hydrobromide.^[1] The listed medicines are quetiapine, pimozide, chlorpromazine, risperidone, olanzapine, ziprasidone, aripiprazole, thioridazine, and haloperidol.^[1]

The study objective is to compare Vortioxetine with treatment as usual in early psychosis, with the main focus on cognition.^[1]

Key patient terms

Treatment as usual means the standard care a patient would normally receive outside the study.^[1] This gives researchers a way to compare the study treatment with regular care.^[1]

Baseline is the first measurement before treatment starts, and Week 24 is the main time point used to check change after treatment.^[1] The study also checks later time points at Week 26 and Week 50.^[1]

Interventional study means the research team gives a treatment rather than only observing people.^[1] In this trial, the goal is to see whether Vortioxetine Hydrobromide can help with cognitive problems in early psychosis.^[1]

Table of Contents

• Trial overview
• Studies in depression and bipolar depression
• Stopping antidepressants safely
• Hot flash study after breast cancer
• What the trials measure
• Study design, phases, and participation

Trial overview

The trial data show that Venlafaxine is being studied in several different research settings, mostly for depression-related conditions.^[1] The studies include people with major depressive disorder, depression, bipolar depression, severe major depressive episodes, and women with hot flashes after breast cancer treatment.^[1][2]

Most of the studies are Phase 3 trials, which means they are testing Venlafaxine in larger groups and comparing outcomes across treatment arms.^{[1][2] One study in adults with major depressive disorder is a Phase 4 trial.[3]}

Studies in depression and bipolar depression

Several trials focus on people with major depressive disorder or related depressive conditions.^{[1][2] One completed Phase 3 study with 25 participants looked at the link between changes in the gut microbial profile, depression symptoms, and side effects during Venlafaxine treatment.[1]}

Another Phase 3 trial in depression is the DEXA-PSYCH study, which includes Venlafaxine among several treatment options in a double-blind, randomised, placebo-controlled design.^[2] Its main goal is to compare change in the MADRS-10 score, a scale that measures depression severity, after 7 days.^[2]

A separate Phase 3 study in people with major depressive disorder is looking at a six-week intensified drug treatment compared with treatment as usual after a first-time treatment failure.^[3] Venlafaxine is one of many medicines used in that study, and the main outcome is change in MADRS total score at six weeks.^[3]

There is also a Phase 3 trial in bipolar depression with the same early-intensified treatment idea and the same main outcome measure, the MADRS total score at six weeks.^[4] The study includes people who had a first-time treatment failure on their first-line treatment.^[4]

One withdrawn Phase 3 study was planned for several diagnoses, including schizophrenia spectrum disorders, major depressive disorder, and bipolar disorder currently in a depressive episode.^[5] It would have compared symptom change over four to six weeks using different rating scales depending on the diagnosis.^[5]

Stopping antidepressants safely

The TEMPO study is a Phase 3 trial in people with stable remitted major depressive disorder, meaning their depression is currently under control.^[6] It compares two tapering strategies for people using Paroxetine or Venlafaxine, with the goal of finding the best way to discontinue antidepressants.^[6]

The main outcome is the rate of failure to successfully discontinue the antidepressant.^[6] This includes switching to rescue medication, stopping the protocol, or having significant withdrawal symptoms during the discontinuation phase.^[6]

Hot flash study after breast cancer

One Phase 3 trial studies women using endocrine therapy after breast cancer.^[7] In this study, Venlafaxine is compared with oxybutynin to see which treatment better reduces hot flashes over 6 weeks.^[7]

The main outcome is the number and severity of hot flashes recorded in a daily Hot Flash Diary.^[7] This makes the study especially focused on symptom tracking in daily life.^[7]

What the trials measure

The trials use different endpoint measures, which are the main results the researchers want to see.^{[1][2] In depression studies, the most common endpoints are changes in depression scores such as MADRS, MADRS-10, or HDRS.[2][3][4][8]}

Some studies look beyond symptoms alone.^{[1][8] The microbiome study measures gut microbial changes, and the ketamine add-on study also explores brain imaging findings with PET-MRI and whether those changes match clinical improvement.[1][8]}

The hot flash trial uses a daily diary to count both the number and severity of symptoms.^[7] The discontinuation trial measures withdrawal symptoms and protocol failures during antidepressant tapering.^[6]

Study design, phases, and participation

Most of the Venlafaxine studies in this dataset are interventional, which means participants receive a planned treatment or comparison treatment.^{[1][2][3][4][6][7]}

The studies are designed for different populations, so participation depends on the condition being studied and the study rules.^{[1][2][3][4][6][7] Some trials focus on adults with depression, some on inpatients with severe major depressive episodes, and one on women after breast cancer treatment.[2][8][7]}

The largest listed study is the withdrawn multi-diagnosis trial with 1,254 planned participants, while the smallest completed study enrolled 25 people.^{[5][1] This shows that Venlafaxine research ranges from small focused studies to large comparative trials.[1][5]}

Table of Contents

• Trial overview
• Safe discontinuation in remitted depression
• Personalized treatment after prior failure
• Main outcomes and measures
• Who can participate
• What these trials may mean for patients

Trial overview

Two authorised Phase 3 clinical trials include Venlafaxine Hydrochloride in research on depressive disorders.^[1][2] Both studies are interventional, which means researchers are testing a planned treatment strategy and measuring the results.^[1][2]

One study focuses on people with currently remitted depressive disorders and looks at antidepressant discontinuation.^[1] The other study focuses on people with depressive disorder who are starting a new antidepressant after prior treatment failure.^[2]

Safe discontinuation in remitted depression

The first trial is titled SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS.^[1] It is authorised, Phase 3, and plans to enroll 150 participants with currently remitted depressive disorders.^[1]

This study compares hyperbolic tapering with linear tapering.^[1] Tapering means lowering the medicine step by step before stopping it.^[1] The study checks whether people can discontinue the antidepressant successfully and stay off it during the 16 weeks after stopping.^[1]

The primary outcome is the proportion of participants who fail to discontinue the antidepressant or restart it during the 16-week follow-up.^[1] Failure to discontinue is defined as continuing the medication beyond the planned tapering schedule, with only a small tolerance period allowed.^[1] This may happen because of withdrawal symptoms or because depressive or anxiety symptoms return.^[1]

The listed antidepressants in this trial include several medicines used in oral form, and Venlafaxine Hydrochloride is part of the broader research topic for this article.^[1]

Personalized treatment after prior failure

The second trial is the PREDICT clinical trial, which is also authorised and in Phase 3.^[2] It plans to enroll 240 participants with depressive disorder.^[2]

This study evaluates a pre-emptive pharmacogenetic strategy for antidepressant selection.^[2] Pharmacogenetic testing means looking at genetic markers to help choose a medicine before treatment starts.^[2] The study compares this personalized approach with standard clinical practice in people who are beginning a new antidepressant after a previous treatment did not work.^[2]

Venlafaxine Hydrochloride appears in the trial’s list of possible antidepressant options as Venlafaxina Retard Sandoz 75 mg, a prolonged-release capsule.^[2] The trial does not study Venlafaxine Hydrochloride alone; it is part of a larger treatment-selection strategy.^[2]

Main outcomes and measures

In the discontinuation trial, the main outcome is whether participants can stop the antidepressant and avoid restarting it during the follow-up period.^[1] This outcome helps researchers understand how well different tapering methods support safe stopping.^[1]

In the PREDICT trial, the main outcome is symptom remission after starting a new antidepressant treatment.^[2] Researchers measure this using changes in PHQ-9 and MADRS scores, which are tools for rating depression severity.^[2]

These outcomes focus on two important questions: can treatment be stopped safely, and can treatment choice be improved for better symptom control?^[1][2]

Who can participate

The first study is for adults with currently remitted depressive disorders.^[1] This means people whose depression is currently improved enough to be considered in remission.^[1]

The second study is for patients with depressive disorder who are starting a new antidepressant after a prior therapy failed.^[2] The study also uses demographic information, clinical information, and data about other medicines taken at the same time.^[2]

• Remitted depression group: people whose depressive disorder is currently not active, so researchers can study stopping antidepressants safely.^[1]
• Depressive disorder group: people who need a new antidepressant after a previous treatment failure, so researchers can test a personalized selection strategy.^[2]

What these trials may mean for patients

These studies are not simple drug comparison trials; they test treatment strategies in real clinical situations.^[1][2] One strategy asks whether antidepressants can be stopped more safely after remission, while the other asks whether treatment choice can be improved using genetic and clinical information.^[1][2]

For patients, the most important point is that the trials are looking at practical outcomes such as staying well, avoiding symptom return, and matching treatment to the person.^[1][2] The available data show that Venlafaxine Hydrochloride is part of this broader depression research, especially in treatment planning and antidepressant selection.^[2]

Table of Contents

• Trial overview
• Who was studied
• What was tested
• Study phase and status
• Main endpoint
• What the results aim to show

Trial overview

The trial data provided here describe one interventional study, which means researchers assigned study treatments to participants rather than only observing them.^[1] The study looked at smoking cessation, which means helping people stop smoking.^[1]

The study title was Use of electronic cigarettes for smoking cessation, and it included Varenicline as a reference treatment for comparison.^[1] The brief summary says the study aimed to assess the efficacy of electronic cigarettes with nicotine compared with electronic cigarettes without nicotine and with the licensed smoking cessation medication Varenicline.^[1]

Who was studied

The trial targeted smokers smoking at least 10 cigarettes/day in the past year.^[1] This means the study focused on people with regular smoking habits, not occasional smokers.^[1]

The provided data do not list other eligibility details, so the main known target group is this smoking population.^[1]

What was tested

The study compared three approaches: electronic cigarettes containing nicotine, electronic cigarettes without nicotine, and Varenicline as the reference medication.^[1] A placebo version of CHAMPIX was also listed, which means an inactive comparison treatment was used in the trial design.^[1]

Because the trial focused on smoking cessation, the comparison was meant to show which approach helped people stay smoke-free more effectively.^[1]

Study phase and status

This was a Phase 3 trial.^[1] Phase 3 studies usually test a treatment in a larger group of people to better understand how well it works in real study conditions.^[1]

The study status was Suspended.^[1] In simple terms, this means the trial was stopped for now and was not continuing as planned in the source data.^[1]

Main endpoint

The main endpoint was the continuous smoking abstinence rate during the last 4 weeks of a 3-month treatment period.^[1] An endpoint is the main result researchers measure to judge whether a study treatment is working.^[1]

In patient terms, this endpoint asks whether people stayed smoke-free without interruption during the last month of treatment.^[1]

What the results aim to show

The study was designed to compare Varenicline with other smoking cessation approaches, especially electronic cigarettes with and without nicotine.^[1] The goal was to evaluate whether these approaches could help people stop smoking, with the main focus on sustained abstinence.^[1]

The enrolled number was planned at 650 participants, showing that this was meant to be a fairly large smoking cessation study.^[1] No numerical results were provided in the source data, so this article only summarizes the study design and goals.^[1]

Table of contents

• Trial overview
• Who can participate
• What is being measured
• Study design and treatment groups
• Why this trial matters

Trial overview

The available trial data describe one interventional study of Vafidemstat in schizophrenia.^[1] The study is titled the EVOLUTION study and is designed to evaluate the efficacy of Vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia.^[1]

This trial is in Phase 2 and has a status of Authorised.^[1] The planned enrollment is 239 participants.^[1]

Who can participate

The study targets adult patients with schizophrenia.^[1] The trial summary says it is meant to assess the effect of Vafidemstat on negative symptoms of schizophrenia in adult patients.^[1]

The source data do not provide more detailed entry rules, such as age limits beyond adulthood, symptom severity thresholds, or other medical requirements.^[1]

What is being measured

The main outcome is the change in the PANSS Factor Score for Negative Symptoms from baseline to week 24.^[1] PANSS is a symptom rating scale used in schizophrenia research, and this part of the score focuses on negative symptoms such as low motivation, less speech, and reduced emotional expression.^[1]

“Baseline” means the starting point before treatment effects are measured, and “week 24” means 24 weeks after the study begins.^[1] This tells researchers whether the treatment group changes more than the placebo group over time.^[1]

Study design and treatment groups

The trial compares Vafidemstat with placebo, which is a look-alike capsule that contains no drug substance.^[1] The placebo capsules are described as Swedish orange colored size 3 capsules that look identical to the Vafidemstat capsules.^[1]

The intervention is given by oral use, meaning it is taken by mouth.^[1] The study is therefore designed to test whether the active treatment leads to better symptom improvement than placebo in a fair comparison.^[1]

Why this trial matters

Schizophrenia can include symptoms that are difficult to treat, especially negative symptoms and thinking problems.^[1] This trial is important because it focuses on those harder-to-treat areas rather than only on general symptom control.^[1]

Because the study is in Phase 2, it is part of the early testing stage that helps show whether a treatment may be useful for larger future studies.^[1] The results will help researchers understand if Vafidemstat deserves further study for schizophrenia.^[1]

Table of Contents

• What is Valbenazine?
• How Does It Work?
• What Conditions Does Valbenazine Treat?
• How is Valbenazine Administered?
• Current Clinical Trials
• Potential Side Effects and Precautions

What is Valbenazine?

Valbenazine Ditosylate, also known as Valbenazine Tosylate or simply Valbenazine, is a medication being studied for its potential to treat certain movement disorders^[1]. It is developed by Neurocrine Biosciences Inc. and is currently undergoing clinical trials to evaluate its effectiveness and safety^[2].

How Does It Work?

Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein in the brain that helps package and transport certain chemicals (neurotransmitters) between brain cells. By inhibiting VMAT2, Valbenazine can help regulate the levels of these neurotransmitters, which may help control involuntary movements associated with certain disorders^[1].

What Conditions Does Valbenazine Treat?

Based on the ongoing clinical trials, Valbenazine is being studied for its potential to treat:

• Schizophrenia: Specifically, it’s being tested as an adjunctive (add-on) treatment for people with schizophrenia who have inadequate response to antipsychotic treatment^[1].
• Dyskinesia due to Cerebral Palsy (DCP): This includes choreiform movements, which are irregular, unpredictable, dance-like movements^[2].

It’s important to note that while these conditions are the focus of current studies, Valbenazine is not yet approved for treating these disorders. The clinical trials aim to determine its effectiveness and safety for these uses.

How is Valbenazine Administered?

Valbenazine is being tested in the form of oral capsules. In the clinical trials, it’s being administered once daily. The dosage varies depending on the study and condition being treated, ranging from 30 mg to 80 mg per day^[1][2].

Current Clinical Trials

There are currently two Phase 3 clinical trials studying Valbenazine:

1. Study for Schizophrenia: This trial is evaluating Valbenazine as an adjunctive treatment for people with schizophrenia who don’t respond adequately to antipsychotic treatment. The main goal is to see if Valbenazine can improve schizophrenia symptoms compared to a placebo^[1].

2. Study for Dyskinesia due to Cerebral Palsy: This trial is testing Valbenazine in both children and adults with dyskinesia (abnormal movements) caused by cerebral palsy. The primary aim is to see if Valbenazine can improve chorea (a type of involuntary movement) in these patients^[2].

Both studies are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either Valbenazine or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.

Potential Side Effects and Precautions

As Valbenazine is still in clinical trials, its full side effect profile is not yet known. However, based on the exclusion criteria in the studies, some precautions are being taken for people with:

• History of long QT syndrome or cardiac arrhythmia
• Moderate or severe liver problems
• History of neuroleptic malignant syndrome
• Substance use disorders
• Suicidal thoughts or behaviors

It’s important to remember that these are precautionary measures for the clinical trials and don’t necessarily reflect confirmed side effects or contraindications^[1][2].

As with any medication, if Valbenazine becomes approved for use, it will be crucial to discuss potential risks and benefits with a healthcare provider before starting treatment.

Table of Contents

• What is Ulotaront?
• What Conditions Does Ulotaront Treat?
• How Does Ulotaront Work?
• Dosage and Administration
• Efficacy of Ulotaront
• Safety and Side Effects
• Ongoing Research

What is Ulotaront?

Ulotaront, also known by its research code SEP-363856, is a new medication being developed for the treatment of various mental health disorders^[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety. Ulotaront is available in tablet form and is taken orally^[2].

What Conditions Does Ulotaront Treat?

Ulotaront is being studied for the treatment of several mental health conditions:

• Major Depressive Disorder (MDD): Ulotaront is being investigated as an additional treatment for adults with MDD who haven’t responded adequately to other antidepressants^[1].
• Generalized Anxiety Disorder (GAD): Clinical trials are evaluating Ulotaront’s effectiveness in treating adults with GAD^[2].
• Schizophrenia: Researchers are studying Ulotaront’s potential in treating acute psychotic symptoms in patients with schizophrenia^[3].

How Does Ulotaront Work?

While the exact mechanism of action is not fully explained in the provided information, Ulotaront (SEP-363856) appears to be a novel medication with a unique way of working. It’s not classified as a typical antidepressant or antipsychotic, which suggests it may have a different approach to treating mental health disorders^[1][2][3]

Dosage and Administration

The dosage of Ulotaront varies depending on the condition being treated:

• For Major Depressive Disorder: Flexible doses ranging from 50 to 75 mg per day are being studied^[1].
• For Generalized Anxiety Disorder: Doses between 50 and 75 mg per day are being evaluated^[2].
• For Schizophrenia: Fixed doses of 50 and 75 mg per day are being tested^[3].

Ulotaront is taken orally, typically once daily. The exact dosing schedule and duration of treatment may vary based on the specific condition and individual patient factors^[1][2][3].

Efficacy of Ulotaront

The effectiveness of Ulotaront is currently being evaluated in clinical trials. Researchers are using various scales to measure its efficacy:

• For Major Depressive Disorder: The Montgomery-Åsberg Depression Rating Scale (MADRS) is being used to assess changes in depression symptoms^[1].
• For Generalized Anxiety Disorder: The Hamilton Anxiety Rating Scale (HAM-A) is being utilized to measure anxiety symptom improvement^[2].
• For Schizophrenia: The Positive and Negative Syndrome Scale (PANSS) is being employed to evaluate changes in psychotic symptoms^[3].

Additionally, the Clinical Global Impression-Severity (CGI-S) scale is being used across all conditions to assess overall illness severity and improvement^[1][2][3].

Safety and Side Effects

As Ulotaront is still in clinical trials, comprehensive safety information is not yet available. However, researchers are closely monitoring various safety aspects, including:

• Adverse events (side effects)
• Physical examinations (including body weight and waist circumference)
• Vital signs (blood pressure, heart rate, and body temperature)
• Electrocardiograms (ECGs)
• Clinical laboratory assessments (blood tests)

Additional safety measures being evaluated include assessments for suicidal thoughts and behaviors, movement disorders, and effects on sleep and sexual function^[1].

Ongoing Research

Ulotaront is currently in Phase 2/3 clinical trials, which means it’s in the later stages of testing but not yet approved for general use. These trials are designed to further evaluate its effectiveness and safety in larger groups of patients^[1][2][3].

It’s important to note that while initial results may be promising, Ulotaront is still an investigational drug. More research is needed before it can be considered for approval by regulatory agencies for widespread use in treating mental health disorders.

Table of Contents

• Trial overview
• OCD efficacy study
• Long-term OCD safety study
• Glioblastoma study
• Main outcomes and endpoints
• Patient glossary

Trial overview

The clinical trials in this dataset study Troriluzole in two main conditions: obsessive compulsive disorder (OCD) and glioblastoma (GBM).^[1][2][3]

All three studies are interventional trials, which means the researchers gave a study treatment and watched what happened.^[1][2][3]

Two trials are Phase 3 studies in OCD, and one trial is a Phase 4 study in GBM.^[1][2][3]

OCD efficacy study

NCT04693351 studied Troriluzole as an added treatment for people with Obsessive Compulsive Disorder who had an inadequate response to their current OCD treatment.^[1]

This was a Phase 3 trial with an enrollment of 700 participants and a status of completed.^[1]

The study compared Troriluzole with placebo, which is a look-alike treatment used for comparison, and it included oral Troriluzole doses of 100 mg and 140 mg.^[1]

The main goal was to see whether Troriluzole improved obsessive-compulsive symptoms more than placebo, using change in the Y-BOCS total score from baseline.^[1]

Long-term OCD safety study

NCT04708834 studied the long-term safety and tolerability of Troriluzole as adjunctive therapy in people with OCD who had not responded well enough to SSRIs, clomipramine, venlafaxine, or desvenlafaxine.^[2]

This was also a Phase 3 study, with an enrollment of 1200 participants and a completed status.^[2]

Participants received oral Troriluzole at 100 mg or 140 mg.^[2]

The study measured safety and tolerability by tracking serious adverse events, adverse events that led to stopping treatment, events judged related to the study medication, and clinically significant laboratory abnormalities.^[2]

Glioblastoma study

NCT03970447 studied Troriluzole in Glioblastoma (GBM), a fast-growing brain cancer.^[3]

This was a Phase 4 interventional study with an enrollment of 1845 participants and a status of authorised.^[3]

The trial tested multiple regimens in newly diagnosed and recurrent GBM and aimed to find experimental therapies that improve overall survival.^[3]

The study also aimed to learn whether certain patient subtypes or biomarkers could help identify who may benefit most, and then confirm promising findings in an expansion stage designed to support a new drug application.^[3]

Main outcomes and endpoints

In the OCD efficacy study, the main endpoint was the change in Y-BOCS total score from baseline, which shows whether obsessive-compulsive symptoms improved.^[1]

In the long-term OCD safety study, the main endpoint focused on safety and tolerability, including serious adverse events, treatment stops caused by side effects, side effects linked to the study drug, and important lab changes.^[2]

In the GBM study, the main endpoint was overall survival, defined as the time from randomization to death from any cause.^[3]

Patient glossary

Adjunctive therapy means a treatment added to the treatment a person is already receiving.^[1][2]

Baseline means the starting point before treatment changes are measured.^[1]

Clinical trial means a research study in people that tests a medical treatment or strategy.^[1][2][3]

Enrollment means the number of people planned or included in a study.^[1][2][3]

Placebo means a treatment that looks like the study drug but is used for comparison.^[1]

Randomization means participants are assigned to a study group by chance.^[3]

Safety and tolerability means how well people can take a treatment without too many harmful effects.^[2]

Serious adverse event means a serious health problem that happens during a study.^[2]

Subtype means a smaller group within a disease that may behave differently from other groups.^[3]

Y-BOCS is a scale used to measure obsessive-compulsive symptoms.^[1]

Table of contents

• Clinical trials overview
• Conditions being studied
• Who can take part
• Trial phases and study design
• Main outcomes and endpoints
• Trial status and enrollment
• Safety-focused studies

Clinical trials overview

The trial data show studies investigating Trospium Chloride in several programs, often as part of KarXT, KarX-EC, or NSC001 research. These studies are looking at whether the treatment is safe and whether it helps symptoms in people with brain and mental health conditions.^[1]

Most of the listed studies are Phase 3 trials, which are later-stage studies that test treatment effects in larger groups. One study is Phase 2, which is an earlier study that focuses more on safety and early signs of benefit.^[1]

Conditions being studied

The trials include people with Alzheimer’s disease, agitation associated with Alzheimer’s disease, and psychosis associated with Alzheimer’s disease.^[1]

Other studies include people with bipolar-I disorder who have mania or mania with mixed features, as well as people with schizophrenia and adolescents with schizophrenia.^[1]

One study also focuses on cognitive impairment, which means problems with thinking, memory, or mental processing.^[1]

Who can take part

Based on the trial data, the target groups include adults with mild to moderate Alzheimer’s disease, adults with agitation or psychosis linked to Alzheimer’s disease, adults with bipolar-I mania, adults with schizophrenia, and teenagers aged 13 to 17 years with schizophrenia.^[1]

Some studies are open to people who are already taking mood stabilizers such as lithium, valproate, or lamotrigine, because one bipolar-I study tests KarXT as an add-on treatment.^[1]

One study is an open-label extension, which means participants know what treatment they are receiving and the study continues for long-term follow-up.^[1]

Trial phases and study design

Most of the trials are interventional, which means the researchers assign a treatment and then measure what happens.^[1]

The Phase 3 studies include both placebo-controlled designs and open-label extension studies. A placebo is a dummy treatment with no active medicine, used for comparison.^[1]

The Phase 2 study in Alzheimer’s disease is a multi-center, randomized, parallel-group, double-blind, placebo-controlled trial. Randomized means participants are put into groups by chance, and double-blind means neither the participant nor the study team knows who gets the active treatment during the study.^[1]

Main outcomes and endpoints

The trials measure different primary outcomes, which are the main results the researchers want to study.^[1]

For agitation in Alzheimer’s disease, the main endpoint is change in the CMAI-IPA total score, which measures agitation symptoms.^[1]

For bipolar-I mania, the main endpoint is change in the Young Mania Rating Scale, or YMRS, at Week 3 or Week 5. This scale measures the severity of manic symptoms.^[1]

For schizophrenia, the main outcome is change in the PANSS total score at Week 6 in one study and at Week 5 in the adolescent study. PANSS is a symptom scale used for schizophrenia.^[1]

For psychosis associated with Alzheimer’s disease, the main endpoint is change in the NPI-C Hallucinations and Delusions score from baseline to the end of treatment.^[1]

For cognitive impairment in Alzheimer’s disease, the main outcomes are ADAS-Cog11 and CIBIC+ at Week 24. ADAS-Cog11 measures thinking and memory, and CIBIC+ looks at overall clinical change.^[1]

Trial status and enrollment

The listed studies are mostly Authorised, with two studies marked Completed and one marked Withdrawn.^[1]

Enrollment ranges from 150 participants in the Phase 2 Alzheimer’s study to 602 participants in an open-label extension study for agitation in Alzheimer’s disease.^[1]

This shows that the research program includes both smaller early studies and larger later-stage studies across different conditions.^[1]

Safety-focused studies

Several trials focus strongly on safety and tolerability, including long-term studies in agitation associated with Alzheimer’s disease, psychosis associated with Alzheimer’s disease, schizophrenia, and bipolar-I mania.^[1]

The Phase 2 Alzheimer’s study measures adverse events, serious adverse events, clinical and neurological findings, vital signs, ECG results, laboratory tests, and suicidal thoughts or behavior using the C-SSRS.^[1]

The long-term extension studies track treatment-emergent adverse events, which are side effects that appear after treatment starts.^[1]

Overall, the trial set is designed to learn whether Trospium Chloride-related study programs can help symptoms while remaining safe in the studied patient groups.^[1]

Table of Contents

• Trial overview
• Study design and groups
• Who can participate
• What is being measured
• Study status and size

Trial overview

The available trial data describe one interventional study of TRAZODONE HYDROCHLORIDE in adults with treatment-resistant depression, which means depression that has not improved enough with usual treatment.^[1] The study is titled “Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ).”^[1]

This study is in Phase 2, so it is looking for early signs that the treatment approach may help and is also monitoring the research process closely.^[1] The status is Authorised.^[1]

Study design and groups

The study is a randomized controlled proof-of-concept study, which means participants are assigned to groups by chance and the results are compared across groups.^[1] The brief summary says the trial is testing a single administration of psilocybin 25 mg plus TRAZODONE HYDROCHLORIDE 30 mg, compared with placebo, with psychotherapeutic support in adult patients with TRD.^[1]

The intervention list shows several study arms, including psilocybin 25 mg capsules, TRAZODONE HYDROCHLORIDE oral drops, and placebo versions for comparison.^[1] In simple terms, the trial is trying to find out whether the active treatment combination works better than inactive comparison treatments.^[1]

Who can participate

The target population in the trial data is adult patients with treatment-resistant depression.^[1] No other detailed eligibility rules are provided in the source data, so the main known requirement is having TRD and being an adult.^[1]

The study also includes psychotherapeutic support, meaning therapy support is part of the research setting for participants.^[1] This tells us the trial is not only testing the study drugs, but also evaluating them in a supported clinical environment.^[1]

What is being measured

The primary outcome is the efficacy of the single administration of the psilocybin plus TRAZODONE HYDROCHLORIDE combination at 1 month.^[1] Efficacy means how well the treatment works.^[1]

Researchers will measure the mean difference in Montgomery-Åsberg Depression Rating Scale (MADRS) scores between baseline and 1 month, comparing the group receiving psilocybin plus TRAZODONE HYDROCHLORIDE with the placebo plus trazodone group.^[1] MADRS is a scale used to rate depression severity, so a change in score helps show whether symptoms improve.^[1]

Study status and size

The trial is listed as Authorised and plans to enroll 112 participants.^[1] This gives a sense of the study size and shows that the research is still in a controlled testing stage rather than routine care.^[1]

Only one trial is provided in the source data, so the current clinical trial picture for TRAZODONE HYDROCHLORIDE here is focused on this single Phase 2 depression study.^[1]

Table of Contents

• What is Tolcapone?
• Medical Conditions Treated with Tolcapone
• How Tolcapone Works
• Dosage and Administration
• Potential Side Effects
• Ongoing Research and Future Potential

What is Tolcapone?

Tolcapone is a medication that belongs to a class of drugs called catechol-O-methyltransferase (COMT) inhibitors. It is also known by the brand name Tasmar^[1]. Tolcapone works by affecting certain chemicals in the brain, particularly dopamine, which is important for various brain functions.

Medical Conditions Treated with Tolcapone

Tolcapone is primarily used to treat several medical conditions:

• Parkinson’s Disease: Tolcapone is approved for use in combination with levodopa and carbidopa to treat Parkinson’s disease symptoms^[1].
• Transthyretin Amyloidosis (ATTR): This is a rare genetic disease where abnormal protein deposits form in various organs. Researchers are studying tolcapone’s potential to stabilize the problematic protein in ATTR^[1].
• Cognitive Disorders: Studies are exploring tolcapone’s effects on cognitive function in conditions like schizophrenia and neurocognitive disorders^[5][10].
• Obsessive-Compulsive Disorder (OCD): Research is being conducted to evaluate tolcapone’s efficacy in treating moderate to severe OCD^[9].
• Pathological Gambling: Some studies have investigated tolcapone’s potential in reducing gambling urges^[3].

How Tolcapone Works

Tolcapone works by inhibiting an enzyme called catechol-O-methyltransferase (COMT). This enzyme is responsible for breaking down certain neurotransmitters, including dopamine. By inhibiting COMT, tolcapone helps to increase the levels of dopamine in the brain^[10].

In Parkinson’s disease, this mechanism helps to prolong the effects of levodopa, a primary treatment for the condition. For other disorders, the increased dopamine levels may help improve cognitive function and reduce certain symptoms^[5].

Dosage and Administration

The dosage of tolcapone can vary depending on the condition being treated and individual patient factors. Here are some general guidelines based on the clinical trials:

• For Parkinson’s disease: Typically, 100mg or 200mg three times a day^[1].
• For research studies: Doses ranged from 100mg to 300mg per day, often divided into multiple doses^[3][5].
• In some studies, the dose was gradually increased over time^[1].

It’s crucial to note that tolcapone should only be taken under the supervision of a healthcare professional, who will determine the appropriate dosage for each individual patient.

Potential Side Effects

As with any medication, tolcapone can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential issues. Common side effects may include:

• Nausea
• Diarrhea
• Fatigue
• Dizziness
• Headache

More serious side effects can occur, particularly related to liver function. Regular liver function tests are typically required for patients taking tolcapone^[5]. Always report any unusual symptoms or side effects to your healthcare provider.

Ongoing Research and Future Potential

Tolcapone is the subject of ongoing research for various conditions:

• Transthyretin Amyloidosis: Studies are investigating tolcapone’s ability to stabilize the transthyretin protein, potentially slowing disease progression^[1].
• Cognitive Enhancement: Researchers are exploring tolcapone’s effects on cognitive function in both healthy individuals and those with conditions like schizophrenia^[5][10].
• Obsessive-Compulsive Disorder: Clinical trials are assessing tolcapone’s efficacy in treating OCD symptoms^[9].
• Sleep and Vigilance: Some studies are looking at how tolcapone affects vigilance and cognitive performance during sleep deprivation^[11].

These ongoing studies may lead to new approved uses for tolcapone in the future, potentially benefiting patients with a variety of conditions.

Table of Contents

• What is Tirzepatide?
• How Tirzepatide Works
• Conditions Treated with Tirzepatide
• How Tirzepatide is Administered
• Current Clinical Trials
• Potential Side Effects
• Special Considerations

What is Tirzepatide?

Tirzepatide is a medication that has gained attention in the medical community for its potential in treating various conditions. It’s known by several names, including LY3298176 (its development code name), Mounjaro, and Zepbound (brand names in certain regions)^[1][2]. Tirzepatide is a unique drug that acts as a dual receptor agonist, meaning it activates two different receptors in the body: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor^[3].

How Tirzepatide Works

Tirzepatide is a 39-amino-acid modified peptide with a special structure that allows it to bind to albumin (a protein in the blood) and prolongs its half-life (the time it takes for half of the drug to be eliminated from the body)^[3]. This means that the medication can stay active in your body for a longer time, allowing for less frequent dosing.

The dual action of tirzepatide on both GIP and GLP-1 receptors is believed to contribute to its effectiveness. These receptors play important roles in regulating blood sugar levels, appetite, and metabolism^[4].

Conditions Treated with Tirzepatide

Tirzepatide is being studied for its potential in treating several conditions:

• Type 2 Diabetes: Tirzepatide has shown promise in helping manage blood sugar levels in people with type 2 diabetes^[5].
• Obesity and Weight Management: Clinical trials are exploring the use of tirzepatide for weight loss in people with obesity^[2].
• Hidradenitis Suppurativa: This is a chronic skin condition characterized by painful, inflamed lesions. A study is investigating tirzepatide’s potential in treating moderate to severe cases^[3].
• Wolfram Syndrome: This rare genetic disorder affects multiple body systems. Researchers are studying tirzepatide as a potential treatment^[4].
• Breast Cancer Risk Reduction: A study is looking at how tirzepatide might affect biomarkers related to breast cancer risk in women with obesity^[6].

How Tirzepatide is Administered

Tirzepatide is typically administered as a subcutaneous (under the skin) injection. It’s usually given once a week, and can be injected in the abdomen, thigh, or upper arm^[1]. The dosage may start low and be gradually increased over time to help your body adjust and minimize side effects^[2].

Current Clinical Trials

Several clinical trials are currently underway to further investigate the effects and potential uses of tirzepatide:

• A study on its use in patients with hormone receptor-positive, HER2-negative breast cancer^[2].
• Research on its effectiveness in people with type 2 diabetes during Ramadan fasting^[5].
• Investigation of its potential in treating Wolfram Syndrome^[4].
• A study on how it affects various biomarkers in women with obesity who are at risk for breast cancer^[6].

Potential Side Effects

As with any medication, tirzepatide may cause side effects. Common side effects reported in clinical trials include:

• Gastrointestinal issues such as nausea, vomiting, or diarrhea^[5].
• Hypoglycemia (low blood sugar), especially in patients with diabetes^[5].

It’s important to discuss potential side effects with your healthcare provider before starting tirzepatide.

Special Considerations

Some special considerations for tirzepatide include:

• Pregnancy and Breastfeeding: A study is being conducted to evaluate tirzepatide concentrations in breast milk, which will provide important information for breastfeeding mothers^[7].
• Body Size: Research is being done to understand how body size might affect the way tirzepatide is absorbed and processed by the body^[1].
• Fasting: A study is looking at how tirzepatide can be used safely and effectively by people with type 2 diabetes who fast during Ramadan^[5].

As tirzepatide is still being studied for many conditions, it’s crucial to consult with your healthcare provider about whether it might be appropriate for you and to stay informed about the latest research findings.

Table of Contents

• What is Thiamine Hydrochloride?
• Medical Uses of Thiamine Hydrochloride
• How Thiamine Hydrochloride is Administered
• Current Research on Thiamine Hydrochloride
• Potential Side Effects and Precautions

What is Thiamine Hydrochloride?

Thiamine Hydrochloride, also known as Vitamin B1, is an essential nutrient that plays a crucial role in various bodily functions. It’s a water-soluble vitamin that helps convert food into energy and is vital for the proper functioning of the heart, nerves, and brain^[1]. Thiamine Hydrochloride is the form of thiamine commonly used in medical treatments and supplements.

This vitamin is also known by several other names, including:^[1]

• Thiamine Chloride
• Aneurine Hydrochloride
• B Complex Vitamin

Medical Uses of Thiamine Hydrochloride

Thiamine Hydrochloride is used to treat or prevent various medical conditions, including:

1. Wernicke-Korsakoff Syndrome (WKS): This is a brain disorder often associated with alcohol dependence. Thiamine deficiency is the primary cause of WKS, and thiamine supplementation is a crucial part of its treatment^[1].
2. Heart Failure: Some studies have shown that thiamine supplementation may improve heart function in patients with chronic heart failure^[2].
3. Septic Shock: Research is being conducted to investigate whether thiamine can help protect kidney function in patients with septic shock, a severe condition where infection leads to dangerously low blood pressure^[3].
4. Thiamine Deficiency in Various Conditions: Thiamine supplementation is used to treat deficiency in conditions such as obesity^[4], alcohol dependence^[1], and after certain types of surgery^[5].
5. Congenital Heart Diseases: Research is being conducted on the potential benefits of thiamine in children with certain types of congenital heart defects^[6].

How Thiamine Hydrochloride is Administered

Thiamine Hydrochloride can be administered in several ways, depending on the condition being treated and its severity:

• Oral Tablets: For less severe cases or preventive measures, thiamine may be given as oral tablets. Dosages can range from 3-5 mg per day for mild cases up to 300 mg per day for more severe conditions^[1][2].
• Intravenous (IV) Injection: In more severe cases or when rapid treatment is needed, thiamine may be given intravenously. Doses can range from 100 mg to 1500 mg per day, depending on the condition^[1][5].
• Intramuscular (IM) Injection: In some cases, thiamine may be administered via intramuscular injection^[1].

The duration of treatment can vary widely, from a few days to several weeks, depending on the condition being treated and the patient’s response to therapy.

Current Research on Thiamine Hydrochloride

Ongoing research is exploring new potential uses for thiamine hydrochloride:

• Prevention of Delirium: A study is investigating whether high-dose intravenous thiamine can prevent delirium in patients undergoing stem cell transplantation^[5].
• Cardiovascular Function in Hyperthyroidism: Researchers are studying if thiamine supplementation can improve cardiovascular function in patients with severe hyperthyroidism^[7].
• Congenital Heart Defects: A study is examining the role of thiamine in improving heart function after certain procedures in children with congenital heart defects^[6].

Potential Side Effects and Precautions

Thiamine Hydrochloride is generally considered safe when used as directed. However, as with any medication, there can be potential side effects:

• Allergic Reactions: In rare cases, some individuals may experience allergic reactions to thiamine, which can include rash, itching, or difficulty breathing.
• Upset Stomach: Some people may experience mild stomach upset when taking oral thiamine supplements.

It’s important to note that these side effects are generally rare, especially when thiamine is given in appropriate doses. Always consult with your healthcare provider before starting any new supplement or medication regimen.

Table of Contents

• What is Thiopental Sodium?
• Medical Uses of Thiopental Sodium
• How Thiopental Sodium is Administered
• Effects of Thiopental Sodium
• Comparison to Other Anesthetics
• Potential Side Effects
• Ongoing Research

What is Thiopental Sodium?

Thiopental sodium, also known as thiomebumal, thiomebumalnatrium, or Pentothal, is a type of medication called a barbiturate^[1][2]. It is used as an intravenous anesthetic, which means it is given through a vein to make patients unconscious for medical procedures^[3]. Thiopental sodium is known for its rapid onset of action, making patients fall asleep quickly^[1].

Medical Uses of Thiopental Sodium

Thiopental sodium is used in several medical scenarios:

• General Anesthesia: It is commonly used to induce anesthesia (put patients to sleep) before surgery or other medical procedures^[3].
• Electroconvulsive Therapy (ECT): Thiopental is used as an anesthetic during ECT, a treatment for severe depression^[4].
• Intracranial Hypertension: In some cases, it is used to treat high pressure inside the skull in patients with severe traumatic brain injury^[5].
• In Vitro Fertilization (IVF): Some studies have investigated its use during egg retrieval procedures for IVF^[6].

How Thiopental Sodium is Administered

Thiopental sodium is always given intravenously (through a vein) by healthcare professionals. The dosage can vary depending on the specific medical situation:

• For general anesthesia, a typical dose might be 2.5 mg per kilogram of body weight^[1].
• For treating high pressure in the brain, higher doses may be used, such as 2-5 mg per kilogram given in stages^[5].

The medication is usually given as a single dose to induce sleep, but in some cases, it may be given as a continuous infusion to maintain unconsciousness^[5].

Effects of Thiopental Sodium

When given thiopental sodium, patients typically experience:

• Rapid onset of unconsciousness: Patients usually fall asleep within 30-60 seconds after the medication is given^[1].
• Short duration of effect: The effects of thiopental sodium wear off quickly, allowing for fast recovery^[4].
• Reduction in brain activity: This can help lower pressure inside the skull in cases of brain injury^[5].

Comparison to Other Anesthetics

Several studies have compared thiopental sodium to other anesthetic medications:

• Propofol: Another commonly used anesthetic. Some studies suggest that propofol may lead to shorter seizure duration in ECT compared to thiopental, but the clinical significance of this is not clear^[4].
• Ketamine: In some surgical procedures, ketamine has been associated with fewer changes in heart rate compared to thiopental^[3].

Potential Side Effects

Like all medications, thiopental sodium can have side effects. Some potential side effects include:

• Lowered blood pressure: Thiopental can cause a drop in blood pressure, which doctors monitor closely^[7].
• Changes in heart rate: Some patients may experience changes in heart rate^[3].
• Respiratory depression: Thiopental can slow down breathing, which is why it’s only used under close medical supervision^[7].

Ongoing Research

Researchers continue to study thiopental sodium to better understand its effects and potential uses:

• Effects on fear and memory: Some studies are investigating how thiopental might affect fear responses and memory formation^[8].
• Use in IVF procedures: Researchers are studying how thiopental might affect fertilization rates in IVF treatments^[6].
• Comparison with other anesthetics: Ongoing studies continue to compare thiopental with other anesthetic medications to determine the best uses for each^[4][7].

Table of Contents

• What is Tiapride?
• Uses of Tiapride
• Dosage Information
• Potential Side Effects
• Ongoing Research

What is Tiapride?

Tiapride, also known by brand names such as Tiapridal, Tiapridex, or Tiapridel, is a medication that belongs to the class of drugs called neuroleptics^[1]. Neuroleptics are a type of medication primarily used to treat various mental health and neurological conditions. Tiapride works by affecting certain chemicals in the brain, which helps to control movement disorders and other symptoms associated with certain conditions.

Uses of Tiapride

Tiapride is used to treat several conditions, including:

• Tic Disorders: Tiapride is used in the treatment of tic disorders, including Tourette Syndrome and Chronic Tic Disorder. Tics are sudden, repetitive movements or sounds that a person makes, often uncontrollably^[2].
• Huntington’s Disease: This is a genetic disorder that causes progressive brain damage, affecting movement, behavior, and cognition. Tiapride is one of the medications used to manage symptoms of Huntington’s Disease, particularly the movement disorders associated with it^[1].
• Psychiatric Conditions: In some cases, Tiapride may be used in the treatment of various psychiatric disorders in elderly patients (gerontopsychiatric patients)^[3].

Dosage Information

The dosage of Tiapride can vary depending on the condition being treated and the age of the patient. Here are some general guidelines based on the available information:

• For Tic Disorders in Children and Adolescents:
  • For patients aged 5-12 years: Starting dose is typically 50mg twice daily for the first 2 weeks, then increased to 100mg twice daily for the next 6 weeks.
  • For patients aged 13-18 years: Starting dose is usually 100mg twice daily for the first 2 weeks, then increased to 200mg twice daily for the next 6 weeks^[2].
• For Huntington’s Disease: The dosage ranges from 300 to 800 mg per day, typically given in tablet form of 100 mg^[1].

It’s important to note that these are general guidelines, and your doctor will determine the right dosage for you based on your individual condition and response to the medication.

Potential Side Effects

Like all medications, Tiapride can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential adverse reactions. Common side effects may include drowsiness, dizziness, or changes in movement. In elderly patients, there may be an increased risk of side effects due to age-related changes in metabolism and the presence of other health conditions^[3].

It’s crucial to report any unusual symptoms or side effects to your healthcare provider. They can help determine if these effects are related to the medication and adjust your treatment plan if necessary.

Ongoing Research

Tiapride continues to be the subject of clinical research to better understand its effectiveness and safety profile:

• A study comparing Tiapride with other medications (Olanzapine and Tetrabenazine) in the treatment of Huntington’s Disease is ongoing. This research aims to evaluate the benefits and side effects of these medications over a 12-month period^[1].
• Another study is investigating the safety of various psychopharmacological treatments, including Tiapride, in elderly psychiatric patients. This research will help to better understand the potential risks and benefits of these medications in older adults^[3].

These ongoing studies highlight the importance of continuous research to improve our understanding and use of medications like Tiapride.

Table of Contents

• What is Testosterone?
• Medical Uses of Testosterone
• Forms and Administration of Testosterone
• Effectiveness of Testosterone Therapy
• Potential Side Effects and Monitoring
• Ongoing Research and Future Directions

What is Testosterone?

Testosterone is a hormone that plays a crucial role in male health. It is primarily produced by the testes in men and is responsible for many masculine characteristics, such as muscle mass, body hair, and deep voice. In medical terms, testosterone is often referred to as an androgen, which means a male hormone^[1].

Medical Uses of Testosterone

Testosterone is primarily used to treat a condition called hypogonadism, which is when the body doesn’t produce enough testosterone on its own. This condition can cause various symptoms, including^[2][3]:

• Low energy levels
• Reduced muscle mass
• Decreased sexual function
• Changes in mood or cognitive function

In addition to hypogonadism, testosterone therapy is also being studied for its potential benefits in certain cases of prostate cancer. While this might seem counterintuitive, some research suggests that in specific situations, testosterone might help manage hormone-refractory prostate cancer, which is a type of prostate cancer that no longer responds to standard hormone therapy^[1].

Forms and Administration of Testosterone

Testosterone replacement therapy comes in several forms, each with its own advantages. Some of the common forms include^[4][1][5]:

• Testosterone pellets (Testopel®): These are small pellets implanted under the skin, usually in the hip area. They slowly release testosterone over several months.
• Transdermal patches (Androderm®): These are patches applied to the skin daily, delivering a steady dose of testosterone.
• Oral capsules: Some forms of testosterone can be taken by mouth, such as testosterone undecanoate (LPCN 1021).

The choice of form depends on various factors, including patient preference, lifestyle, and specific medical needs.

Effectiveness of Testosterone Therapy

The effectiveness of testosterone therapy is typically measured by monitoring testosterone levels in the blood and assessing symptom improvement. Studies have shown that testosterone replacement can effectively raise testosterone levels to the normal range in most patients with hypogonadism^[2][3].

For example, one study found that after 24 days of treatment with oral testosterone undecanoate, a significant proportion of patients achieved normal testosterone levels^[2]. Another study using testosterone pellets showed that testosterone levels could be maintained in the therapeutic range for 4-6 months after a single implantation^[4].

Potential Side Effects and Monitoring

While testosterone therapy can be beneficial, it’s important to be aware of potential side effects. Regular monitoring is crucial to ensure safe and effective treatment. Some key aspects that are typically monitored include^[4][5]:

• Testosterone levels: To ensure they remain within the normal range.
• Hematocrit levels: Testosterone can increase red blood cell production, which might lead to blood thickening in some cases.
• PSA (Prostate Specific Antigen) levels: To monitor prostate health, as testosterone might affect the prostate gland.
• Estradiol levels: Some testosterone can be converted to estrogen in the body, so estradiol (a form of estrogen) is also monitored.
• Blood pressure: Some studies are investigating the effects of testosterone on blood pressure.

Ongoing Research and Future Directions

Research on testosterone therapy is ongoing, with scientists exploring its potential benefits and risks in various conditions. Some areas of current research include^[6][5]:

• The use of new imaging techniques, such as PET scans with special tracers, to better understand how testosterone interacts with prostate cancer cells.
• The effects of testosterone therapy on cardiovascular health, including blood pressure.
• The potential benefits of testosterone on quality of life, sexual function, and muscle strength in men with low testosterone levels.

These ongoing studies aim to provide a more comprehensive understanding of testosterone’s role in health and disease, potentially leading to improved treatments in the future.

Table of Contents

• What is Sulpiride?
• Medical Uses
• How Sulpiride Works
• Dosage and Administration
• Side Effects
• Research and Clinical Trials
• Considerations for Patients

What is Sulpiride?

Sulpiride is a medication that belongs to a class of drugs called antipsychotics. It is also known by the brand name Dogmatil^[1]. Sulpiride is primarily used to treat various mental health conditions and has been the subject of numerous clinical trials to explore its effectiveness and potential applications.

Medical Uses

Sulpiride is used to treat several conditions, including:

• Schizophrenia: This is a serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior^[2].
• Menopausal syndrome: Sulpiride has been studied for its potential to reduce hot flashes during menopause^[3].
• Nausea and vomiting: Some studies have explored the use of sulpiride as an antiemetic (anti-nausea) medication^[4].
• Depression: In some cases, sulpiride may be used to treat depressive symptoms, although this is not its primary use^[5].

How Sulpiride Works

Sulpiride is a selective dopamine D2 receptor antagonist. This means it blocks the action of dopamine, a neurotransmitter (chemical messenger) in the brain. By doing so, it can help regulate mood, thinking, and behavior^[5].

In low doses (50-200 mg), sulpiride may increase dopamine levels by blocking certain receptors, which could help with depressive symptoms. However, at higher doses, it primarily blocks dopamine receptors, which is how it works to treat conditions like schizophrenia^[5].

Dosage and Administration

The dosage of sulpiride can vary depending on the condition being treated and the individual patient. Some examples from clinical trials include:

• For schizophrenia: Doses ranging from 400 mg to 800 mg per day have been studied^[6].
• For menopausal hot flashes: A dose of 50 mg once daily for 60 days was used in one study^[3].
• As an antiemetic: A dose of 100 mg was used in a study examining its effects on bowel preparation before colonoscopy^[4].

It’s important to note that these dosages are from clinical trials and may not reflect the typical prescribed doses. Always follow your doctor’s instructions regarding medication use.

Side Effects

Like all medications, sulpiride can cause side effects. Some potential side effects include:

• Increased prolactin levels: This can lead to symptoms such as breast enlargement or milk production^[5].
• Extrapyramidal symptoms: These are movement disorders that can include tremors, muscle stiffness, or involuntary movements^[6].
• Changes in blood pressure and heart rate^[5].
• Mood changes^[5].

It’s important to discuss potential side effects with your healthcare provider.

Research and Clinical Trials

Sulpiride has been the subject of various clinical trials exploring its effectiveness and potential new uses:

• A study investigated its use in reducing hot flashes during menopause^[3].
• Another trial examined its potential as an antiemetic for patients undergoing bowel preparation before colonoscopy^[4].
• Researchers have studied its effects on working memory, motivation, and learning^[5].
• A trial compared the effectiveness of sulpiride alone versus a combination with amisulpride in treating schizophrenia^[6].

Considerations for Patients

If you’re prescribed sulpiride, keep these points in mind:

• Always take the medication as prescribed by your doctor.
• Do not stop taking sulpiride suddenly without consulting your healthcare provider, as this can lead to withdrawal symptoms or a relapse of your condition.
• Inform your doctor about all other medications you’re taking, as sulpiride can interact with other drugs.
• Regular check-ups may be necessary to monitor for side effects and adjust the dosage if needed.
• If you experience any unusual symptoms or side effects, contact your healthcare provider immediately.

Remember, while this information provides a general overview of sulpiride, it’s crucial to consult with your healthcare provider for personalized advice and treatment.

Table of Contents

• Clinical trials overview
• Neurology and emergency seizure studies
• Cancer studies
• Pediatric and rare disease studies
• Psychiatry studies
• Women’s health study
• Main outcomes used in the trials

Clinical trials overview

The trial data show that Sodium Valproate is being studied in several different diseases, not just one condition.^[1][2][3]

These studies include interventional trials, which means the researchers give a treatment and then measure what happens.^[1]

The trial phases range from Phase 1 to Phase 4, so the research includes early safety work and later studies that look at treatment benefit in larger groups.^[2][3]

Neurology and emergency seizure studies

Several trials focus on seizure-related conditions, including status epilepticus, which is a medical emergency involving ongoing or repeated seizures.^[4][5]

In NCT05263674, the FAST TRIAL, researchers compare intravenous Sodium Valproate with other anti-seizure and sedation treatments in people with status epilepticus, and the main outcome is treatment failure after 24 hours.^[5]

In NCT06549426, the TELSTAR-2 trial studies comatose cardiac arrest patients with status epilepticus on continuous EEG, and it asks whether stepwise anti-seizure treatment improves functional recovery at six months.^[4]

The TELSTAR-2 primary outcome is the score on the extended Glasgow Outcome Scale (eGOS), which measures recovery after brain injury or severe illness.^[4]

Cancer studies

One Phase 1 study, NCT06199557, looks at Sodium Valproate in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who are considered unfit for standard chemotherapy.^[2]

This trial tests combinations with hydroxyurea or 6-mercaptopurine and focuses on safety and tolerability, including adverse events, dose-limiting toxicities, lab tests, and physical exams.^[2]

It also measures early signs of clinical benefit and changes in Eastern Cooperative Oncology Group (ECOG) performance status, which is a score that shows how well a person can carry out daily activities.^[2]

In 2024-516844-25-01, the REVOLUTION study tests whether adding valproic acid and Sodium Valproate to bevacizumab and oxaliplatin/fluoropyrimidine regimens can improve progression-free survival in people with RAS-mutated metastatic colorectal cancer.^[6]

Pediatric and rare disease studies

The AUDIOWOLF study, NCT04940572, is a Phase 2 trial in people with Wolfram syndrome due to a monogenic mutation.^[7]

Its main goal is to see whether daily Sodium Valproate can preserve hearing over three years, using audiometry and high-frequency hearing tests.^[7]

Another Phase 2 study, 2022-502332-39-00, includes children with tuberous sclerosis complex under 4 months of age and measures neuropsychologic outcome at 24 months using the cognitive scale of the Bayley Scales of Infant and Toddler Development III (BSID-III).^[8]

In the ependymoma program NCT02265770, Sodium Valproate appears in one treatment stratum for children unable to receive radiation therapy, where the study evaluates progression-free survival when valproate is added to the main chemotherapy strategy.^[3]

Psychiatry studies

Two Phase 3 studies include people with mood and other psychiatric disorders.^[9][10]

NCT05973786 studies a six-week intensified drug plan for bipolar depression in people who had a first-time treatment failure on first-line treatment, and it measures change in symptom severity using the Montgomery-Åsberg Depression Rating Scale (MADRS).^[9]

NCT05603104 was a larger Phase 3 study in schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder, and bipolar depression, but the trial status is withdrawn.^[10]

That withdrawn study also measured symptom change, using the Positive and Negative Syndrome Scale for schizophrenia and MADRS for major depressive disorder and bipolar depression.^[10]

Women’s health study

In 2025-523076-23-00, researchers are studying women of reproductive age with adenomyosis in a Phase 2 trial.^[11]

The trial compares a plan that includes a single intralesional administration of valproic acid followed by oral dosing with placebo-based comparators, and it looks at pelvic pain and rescue medication use over 29 days.^[11]

The primary endpoint uses change in AAPP, which is the trial’s pain measure, and it also records how much ibuprofen is needed as rescue medicine.^[11]

Main outcomes used in the trials

The studies use different endpoints because they are asking different clinical questions.^[1][2][3]

• Functional recovery is used in the post-cardiac arrest trial and is measured by eGOS at six months.^[4]

• Safety and tolerability are central in the leukemia trial, where the team tracks adverse events, exams, and lab results.^[2]

• Hearing preservation is the key outcome in Wolfram syndrome, with testing over three years.^[7]

• Progression-free survival is used in the colorectal cancer and ependymoma studies to see how long the disease stays controlled.^[6][3]

• Symptom severity is measured in the bipolar depression study using MADRS, while the withdrawn psychiatric study used both MADRS and PANSS depending on the diagnosis.^[9][10]

• Neuropsychologic outcome is measured in young children with tuberous sclerosis complex using blinded testing at 24 months.^[8]

Table of contents

• Overview of the research
• Who the trials include
• What the trials are trying to measure
• Trial phases and study status
• Key studies in the data
• Helpful terms for patients

Overview of the research

The trial data show that Sodium Oxybate is being studied in several different clinical settings, including brain disease, sleep medicine, addiction-related care, psychiatry, and intensive care.^{[1][2][3][4][5][6][7][8]}

These are interventional studies, which means the research team gives a treatment or compares treatments and then measures the results.^{[1][2][3][4][5][6][7][8]}

Who the trials include

The studies focus on different patient groups, so the people who may take part are not the same in every trial.^{[1][2][3][4][5][6][7][8]}

• People with cerebral amyloid angiopathy, a condition where amyloid builds up in brain blood vessels, are included in the Clear-Brain study.^[1]

• Adults with narcolepsy are included in a Phase 3 switch study that looks at blood pressure after changing treatment.^[2]

• People with alcohol addiction and a high or very high drinking risk level are included in a Phase 3 study of alcohol reduction and abstinence.^[5]

• Psychiatric patients with catatonia are included in a randomized study comparing Sodium Oxybate with lorazepam.^[6]

• Patients with GHB use disorder are included in detoxification studies that test whether baclofen can reduce the need for pharmaceutical GHB.^[4][7]

• Adults in the intensive care unit who have been hospitalized for more than 48 hours are included in a pilot sleep study, with or without mechanical ventilation.^[8]

• One study also includes people with intoxication and tests whether potential biomarkers can be detected longer than GHB itself in blood.^[3]

What the trials are trying to measure

Each trial has a primary endpoint, which is the main result used to judge the study.^{[1][2][3][4][5][6][7][8]}

• In cerebral amyloid angiopathy, the main endpoint is the morning levels of Aβ 40 and 42 in CSF, measured before and after treatment by lumbar puncture, which is a needle test to collect spinal fluid.^[1]

• In narcolepsy, the main endpoint is the change in 24-hour average SBP, which means systolic blood pressure, from the start of the study to the end-of-treatment visit.^[2]

• In the intoxication study, the main endpoint is the time until the longest detectable biomarker in blood is no longer changed in the treatment group compared with placebo, which is an inactive comparison treatment.^[3]

• In the GHB use disorder detoxification study, the main endpoint is the pharmaceutical GHB dose at the end of the titration phase during inpatient detoxification, which shows how much treatment is still needed.^[4][7]

• In alcohol addiction, the main endpoint is the reduction in HDDs, or heavy drinking days, after 3 months of treatment.^[5]

• In catatonia, the main endpoint is the response rate after four days, measured by the change in BFCRS scores, with response defined as a 50% reduction in symptoms.^[6]

• In the ICU sleep study, the main endpoint is the duration of deep slow-wave sleep, also called N3 stage, measured in minutes on sleep recordings.^[8]

Trial phases and study status

The data include Phase 2 and Phase 3 studies, plus one low-intervention trial.^{[1][2][3][4][5][6][7][8]}

Several studies are marked Authorised, two are Completed, and one is Withdrawn.^{[1][2][3][4][5][6][7][8]}

• Phase 2 studies in the data include cerebral amyloid angiopathy, GHB use disorder, and ICU sleep research.^[1][4][7][8]

• Phase 3 studies include narcolepsy, alcohol addiction, and catatonia.^[2][5][6]

• The completed studies are the narcolepsy switch study and the intoxication biomarker study.^[2][3]

• The withdrawn study is one of the inpatient GHB detoxification studies.^[4]

Key studies in the data

The Clear-Brain trial is a Phase 2 study in cerebral amyloid angiopathy and looks at whether treatment can increase amyloid-beta clearance from brain blood vessels, using CSF Aβ 40 and 42 as the main outcome.^[1]

The narcolepsy study is a Phase 3 switch trial that tests whether moving from high-sodium oxybate to XYWAV changes 24-hour blood pressure.^[2]

The intoxication trial is a low-intervention study that asks whether certain biomarkers in blood stay detectable longer than GHB itself.^[3]

The inpatient detoxification studies in GHB use disorder test whether baclofen add-on treatment lowers the amount of pharmaceutical GHB needed during titration.^[4][7]

The alcohol addiction study is a Phase 3 trial focused on reducing heavy drinking days and helping maintain abstinence in people with high drinking risk.^[5]

The catatonia study is a randomized Phase 3 trial comparing Sodium Oxybate with lorazepam and measuring symptom response after four days using BFCRS scores.^[6]

The ICU pilot study is a Phase 2 double-blind randomized controlled trial, which means neither the participants nor the researchers know who gets the study treatment, and it measures deep sleep time in critically ill adults.^[8]

Helpful terms for patients

Randomized controlled trial means people are assigned by chance to different groups so the results are more reliable.^[6][8]

Double-blind means the patient and the study team do not know which treatment is being given during the study.^[8]

Placebo means an inactive treatment used for comparison in research.^[3]

Lumbar puncture is a procedure that collects CSF from the lower back for testing.^[1]

Titration phase means a period when treatment is adjusted to find the right dose or amount used in the study.^[4][7]

Abstinence means not using alcohol.^[5]

Critical care or ICU care means treatment in a hospital unit for very sick patients who need close monitoring.^[8]

Biomarker means a measurable sign in the body, such as a blood or fluid test result, that researchers use to follow a disease or treatment effect.^[3]

Table of contents

• Trial overview
• Study design and phases
• Who can participate
• What is being measured
• What the study is trying to find
• Key terms explained

Trial overview

The trial NCT03094429 is an interventional study of SODIUM BENZOATE in adults with refractory schizophrenia.^[1] It is designed as an add-on study with clozapine and compares SODIUM BENZOATE with placebo.^[1]

The study status is Authorised, and the planned enrollment is 278 participants.^[1]

Study design and phases

This is an adaptive, double-blind, randomized, placebo-controlled, two-part, dose-finding, multi-center study.^[1] Adaptive means the study plan can be adjusted based on early results, while dose-finding means it tries to identify the best dose for the later part of the trial.^[1]

The trial is listed as Phase 4.^[1] In Part 1, the study compares 1000 mg/day and 2000 mg/day with placebo to evaluate dose-response and choose the optimal dose for Part 2.^[1] In Part 2, the selected dose is compared with placebo again to test effectiveness with clozapine.^[1]

Who can participate

The study is for adults with refractory schizophrenia.^[1] The trial summary says it focuses on people who still have residual symptoms while taking clozapine.^[1]

Based on the trial data, participation is meant for patients whose symptoms have not fully improved with current treatment, rather than for people with a different condition.^[1]

What is being measured

The primary outcome is the mean change from baseline in the Positive and Negative Syndrome Scale, or PANSS, total score after 8 weeks of randomized treatment.^[1] Baseline means the starting point before the trial treatment begins.^[1]

PANSS is a symptom score used in schizophrenia studies to track changes in overall illness severity.^[1] A lower score after treatment may suggest improvement, but the trial data only states that this score is being measured.^[1]

What the study is trying to find

Part 1 aims to compare SODIUM BENZOATE doses of 1000 mg/day and 2000 mg/day against placebo when added to clozapine.^[1] The researchers want to see which dose works best for improving residual symptoms in adults with refractory schizophrenia.^[1]

Part 1 also includes a sample size re-assessment, which means the team checks whether the planned number of participants is enough to continue into Part 2.^[1] Part 2 then tests the chosen optimal dose against placebo to confirm its effect.^[1]

Key terms explained

Placebo-controlled means the study compares the active study treatment with a look-alike treatment that has no active medicine.^[1]

Randomized means participants are assigned to study groups by chance.^[1]

Double-blind means neither the participants nor the study team know who is receiving which treatment during the study.^[1]

Residual symptoms are symptoms that remain even after treatment has started.^[1]

Refractory schizophrenia means schizophrenia that does not respond well enough to standard treatment.^[1]

Table of Contents

• Overview of the trials
• Trial 1: Early intensified treatment after first treatment failure
• Trial 2: Maintenance treatment after remission from first episode psychosis
• What the trials measure
• Who the studies are for
• Study design and phases

Overview of the trials

The trial data show two Phase 3 studies that include Sertindole as one of several antipsychotic medicines being studied.^[1][2] Both studies are interventional, which means researchers assign treatment strategies and then measure the results.^[1][2]

These trials are not simple drug-only studies. They compare treatment approaches in people with psychosis-related conditions, such as schizophrenia or remission after a first episode of psychosis.^[1][2]

Trial 1: Early intensified treatment after first treatment failure

NCT05958875 is a randomised, controlled trial in people with schizophrenia, schizoaffective disorder, or schizophreniform disorder who had a first-time treatment failure on their first-line treatment.^[1] The study compares a six-week intensified pharmacological treatment with treatment as usual.^[1]

Sertindole is one of the medicines listed in the intensified treatment options, along with several other antipsychotic medicines such as quetiapine, risperidone, olanzapine, clozapine, and others.^[1] The trial is authorised, is in Phase 3, and plans to include 418 participants.^[1]

The main question is whether early intensified treatment improves symptoms more than usual care over six weeks.^[1]

Trial 2: Maintenance treatment after remission from first episode psychosis

The second study, HAMLETT, looks at people who are in remission after a first episode of psychosis.^[2] It compares continuing antipsychotic medication for at least one year with early dose reduction or discontinuation.^[2]

Sertindole is listed among the antipsychotic medicines included in this study, together with haloperidol, clozapine, paliperidone, olanzapine, risperidone, and others.^[2] The trial is authorised, is in Phase 3, and plans to enroll 444 participants.^[2]

This study focuses on long-term personal and social functioning, not only short-term symptom control.^[2]

What the trials measure

The first trial uses the PANSS total score as its primary outcome.^[1] PANSS stands for Positive and Negative Syndrome Scale, a standard way to measure symptom severity in psychosis.^[1] The study compares the mean change from baseline to six weeks between the two treatment arms.^[1]

The second trial uses a long-term social recovery measure based on what patients and relatives said matters most, and this is quantified with the WHODAS-II tool.^[2] WHODAS-II stands for World Health Organization Disability Assessment Schedule and is used to measure daily functioning and social participation.^[2]

Who the studies are for

The first study is for people with schizophrenia, schizoaffective disorder, or schizophreniform disorder who had a first treatment failure on their first-line therapy.^[1] This makes the study relevant for patients whose first treatment did not work well enough.^[1]

The second study is for patients who have recovered enough to be in remission after a first episode of psychosis.^[2] This group is being studied because researchers want to know whether staying on medication is better than reducing or stopping it early.^[2]

Study design and phases

Both trials are interventional and Phase 3, which means they are testing treatment strategies in larger groups and looking at real clinical outcomes.^[1][2] One study is randomised and controlled, while the other compares continuation with dose reduction or discontinuation in a long-term setting.^[1][2]

Together, the studies show that Sertindole is being examined within broader treatment plans for psychosis, rather than as a stand-alone focus.^[1][2]

Table of contents

• Clinical trials overview
• Who may participate
• Conditions studied in the trials
• Study phases and designs
• Outcomes measured
• Trial highlights
• Patient-friendly terms

Clinical trials overview

These studies investigate Sertraline in several research settings, mostly for mental health conditions and one non-psychiatric cancer setting.^[1][2] The trials compare Sertraline with other treatment strategies, placebo, or treatment as usual, depending on the study question.^[1][3]

Some studies focus on whether Sertraline is part of a better treatment plan after a first treatment has failed, while others look at personalized medicine, tapering off antidepressants, or symptom control in specific patient groups.^[3][4][5]

Who may participate

The target populations include adults with major depressive disorder, bipolar depression, remitted depressive disorders, and depressive symptoms linked to heart failure with preserved ejection fraction.^[1][2][3][4]

Other studies include people with anxiety disorders, psychotic disorders, schizophrenia-related disorders, and patients with advanced gastroesophageal cancer receiving immunochemotherapy.^[5][6] One study also includes adults with depression who need a new antidepressant after previous treatment failure.^[7]

Conditions studied in the trials

Several trials focus on depression in different forms, including standard depression, bipolar depression, and depression that has already improved but may return when treatment is stopped.^[2][3][7] One study looks at people with heart failure and mood symptoms, using a cardiovascular outcome as the main endpoint.^[1]

A separate trial studies Sertraline in a cancer setting, where the goal is to see whether it may help improve response to first-line immunochemotherapy in metastatic gastroesophageal adenocarcinoma.^[6] This is different from the mental health studies because the main focus is cancer response, not mood symptoms.^[6]

Study phases and designs

Most of the Sertraline trials in the data are Phase 3 studies, which means they are testing the treatment in larger groups and comparing it with other strategies or usual care.^{[1][2][3][4][5][7]}

There is also one Phase 2 study in advanced gastroesophageal cancer, which is a smaller and earlier study aimed at learning more about treatment response.^[6] One completed study is Phase 4 and looks at adjunctive therapy in adults with major depressive disorder after an inadequate response to an initial antidepressant trial.^[8]

The designs include interventional trials, meaning the researchers assign treatment strategies and then measure what happens.^[1][2] Some studies compare intensified treatment with treatment as usual, while others compare different tapering methods or personalized dosing plans.^[3][4][5][7]

Outcomes measured

The main outcomes include changes in depression symptom scores, such as the MADRS and PHQ-9, which help show whether symptoms improve after treatment starts.^[2][3][7]

Other outcomes include the proportion of patients who can stop antidepressants without restarting them, patient recovery at 24 weeks, and time to hospitalization for cardiovascular reasons or death from any cause.^[1][4][5]

The cancer trial uses a different outcome: the best tumor response after at least one cycle of immunochemotherapy, measured with RECIST 1.1 criteria.^[6] This shows that the same medicine can be studied for very different goals depending on the disease area.^[6]

Trial highlights

• Heart failure study: This completed Phase 3 trial followed 485 people with heart failure with preserved ejection fraction and depressive-anxiety symptoms, and it measured time to cardiovascular hospitalization or death.^[1]

• Discontinuation study: This authorised Phase 3 study in 150 people with remitted depressive disorders looks at whether antidepressants can be stopped safely without restarting during 16 weeks after tapering.^[2]

• Bipolar depression study: This authorised Phase 3 trial in 458 participants compares intensified treatment with usual care after first-line treatment failure and uses change in MADRS score at six weeks as the main outcome.^[3]

• Depression study with dexamethasone add-on: This authorised Phase 3 trial includes 300 participants with depression and measures change in MADRS-10 score at day 7.^[4]

• Personalized psychiatry studies: These authorised Phase 3 trials test pharmacogenetics, which means using genetic information to help choose treatment, in large psychiatric groups that include mood, anxiety, and psychotic disorders.^[5][7]

• Cancer study: This authorised Phase 2 trial includes 35 patients with gastroesophageal cancer and looks at tumor response after immunochemotherapy.^[6]

Patient-friendly terms

Treatment as usual means the standard care that participants would normally receive outside the trial.^[3][4]

Tapering means slowly lowering a medicine dose over time instead of stopping all at once.^[2]

Withdrawal symptoms are unwanted symptoms that can appear when a medicine is reduced or stopped.^[2]

Biomarkers are measurable signs in the body, such as blood or tissue markers, that researchers use to study disease or treatment effects.^[1]

Pharmacogenetics means studying whether genes can help predict which treatment may work best for a person.^[5][7]

Table of contents

• Clinical trials overview
• Who the trial is for
• How the study is designed
• What the researchers measure
• Trial status and size
• Key terms explained

Clinical trials overview

The available trial is studying SELTOREXANT in adults with major depressive disorder with insomnia symptoms, also called MDDIS in the study summary.^[1] It is designed to see whether SELTOREXANT can help improve depressive symptoms when used together with an SSRI or SNRI antidepressant.^[1]

The study also looks at whether SELTOREXANT can help delay relapse, which means symptoms coming back after improvement.^[1] The trial includes both short-term testing and a longer maintenance phase.^[1]

Who the trial is for

This study is for adult depressed patients with insomnia symptoms who have had an inadequate response to their current SSRI or SNRI antidepressant therapy.^[1] In simple terms, this means their current treatment has not helped enough.

The trial summary shows that SELTOREXANT is being studied as an adjunctive therapy, which means it is added to another antidepressant rather than replacing it.^[1]

How the study is designed

This is a Phase 3 interventional trial, which means researchers are actively giving study treatment and comparing outcomes in a larger group of people.^[1] The study is authorised and plans to enroll 752 participants.^[1]

The trial includes a comparison with placebo, which is a look-alike treatment with no active study medicine.^[1] The summary also describes an open-label part, where treatment is given in a way that is not blinded, followed by a double-blind maintenance phase.^[1]

In a double-blind phase, participants and study staff do not know who is receiving which treatment, which helps reduce bias in the results.^[1]

What the researchers measure

The main short-term measure is the change from baseline to Day 43 in the MADRS total score.^[1] MADRS is a depression rating scale used to measure how severe depressive symptoms are and whether they improve.

The longer-term measure is the time from randomization to the first relapse during the double-blind maintenance phase in participants who had a stable response after open-label SELTOREXANT treatment.^[1] This tells researchers how long symptom improvement lasts before depression returns.

The study summary says the trial is also evaluating safety for both short- and long-term use when SELTOREXANT is taken with another antidepressant.^[1]

Trial status and size

The trial status is listed as Authorised.^[1] The planned enrollment is 752 participants, which suggests a large Phase 3 study.^[1]

The registered trial ID is 2023-509070-36-00.^[1]

Key terms explained

Randomization means participants are assigned to a study group by chance, so the groups can be compared fairly.^[1]

Open-label means everyone knows what treatment is being given during that part of the study.^[1]

Maintenance phase means a later part of the study that checks whether benefits last over time.^[1]

Relapse means symptoms return after they had improved.^[1]

Table of Contents

• Clinical trials overview
• Conditions being studied
• Who can take part
• Trial phases and study design
• Main endpoints being measured
• Special and less common research areas
• What these trials may help answer

Clinical trials overview

These studies investigate Semaglutide in many different settings, often as an add-on to standard care or compared with placebo.^[1][2] The trial data include studies in chronic kidney disease, type 2 diabetes, obesity, heart and blood vessel disease, stroke, infertility, liver disease, and several other conditions.^[1][3]

Many trials are designed to see whether Semaglutide improves a main outcome such as blood sugar, body weight, kidney markers, or disease-specific measures.^[2][4] Several studies also look at safety, tolerability, and whether treatment works better than placebo or another active treatment.^[5]

Conditions being studied

Type 2 diabetes is the most common condition in the dataset, and it appears in many adult and pediatric studies.^[2][6] These trials often measure HbA1c, which is a blood test showing average blood sugar over time.^[6]

Obesity is another major research area, including studies in adults, adolescents, children, and people with obesity plus other health problems such as atrial fibrillation, resistant hypertension, heart failure, HIV, or sleep apnea.^[7][8] Several obesity trials measure body weight, BMI, or percent weight loss as the main result.^[7]

Chronic kidney disease is studied in more than one trial, including studies that measure urine albumin-to-creatinine ratio, also called UACR, and estimated kidney function decline.^[1][9] Some kidney studies include people with type 2 diabetes, obesity, or both, while others include chronic kidney disease more broadly.^[1][9]

There are also trials in cardiovascular disease, coronary artery disease, stroke, glaucoma, Alzheimer’s disease, alcohol use disorder, cannabis use disorder, and diabetic foot ulcer.^[3][10] This shows that Semaglutide is being studied far beyond weight and glucose control in the trial program.^[3]

Who can take part

The target populations vary widely across studies.^[2] Some trials include adults with type 2 diabetes, while others focus on children, teenagers, or young adults with obesity.^[6][7]

Several studies include people with extra health risks, such as overweight or obesity plus heart disease, prediabetes, kidney disease, or treatment with antipsychotic medicines.^[8][11] Some trials also have very specific groups, such as people with schizophrenia taking clozapine or olanzapine, women with prior gestational diabetes, or patients after kidney transplant.^[11][12]

A few studies are in children or adolescents with obesity, including those with hypothalamic obesity secondary to craniopharyngioma or obesity linked to antipsychotic treatment.^[7][13] Other studies focus on adults with conditions such as atrial fibrillation, resistant hypertension, or diabetic neuropathy.^[8][14]

Trial phases and study design

Most of the Semaglutide trials in the data are Phase 2 or Phase 3 studies.^[2] Phase 2 trials usually explore whether the treatment may work and continue to watch for safety, while Phase 3 trials are larger and are used to confirm benefit more strongly.^[2]

There are also some Phase 1 studies, such as the oral Semaglutide and dapagliflozin combination study in healthy participants.^[4] In that setting, the main goal is to understand how the medicines behave in the body when given together.^[4]

A few studies are listed as low intervention, which means the research uses limited extra intervention beyond routine care or simple study procedures.^[5] Several trials are randomized, placebo-controlled, or open-label, depending on the question being asked.^[5]

Main endpoints being measured

The most common endpoint in the trial data is change in HbA1c, especially in type 2 diabetes studies.^[6] This endpoint is used to see whether blood sugar control improves over time.^[6]

Weight-related studies often measure change in body weight, BMI, or percent total weight loss.^[7][13] Some studies also use thresholds such as achieving at least 5% weight loss or maintaining BMI below an obesity threshold.^[7][13]

Kidney studies often use UACR or chronic eGFR slope, which is the rate of long-term kidney function change.^[1][9] Heart and blood vessel studies may measure major adverse cardiovascular events, blood pressure, rhythm outcomes, or plaque changes on heart imaging.^[8][10]

Some trials use more specialized endpoints, such as modified Rankin Scale after stroke, good quality blastocysts in IVF, wound closure in diabetic foot ulcer, or gene expression in Alzheimer’s disease.^[14][15] These endpoints show that the studies are asking very different clinical questions, not only weight or glucose questions.^[15]

Special and less common research areas

Several trials explore Semaglutide in areas that are not the usual diabetes or obesity setting.^[10] For example, some studies look at diabetic retinopathy, glaucoma, multiple sclerosis, depression, alcohol use disorder, cannabis use disorder, and chemsex-related drug craving.^[10][16]

Other studies focus on inflammation, endothelial biomarkers, bone turnover, platelet reactivity, liver fat, or hepatic fibrosis.^[3][9][17] These are all biological signs that may help explain whether the treatment changes disease activity, not just symptoms.^[17]

Some trial titles also mention combination approaches, such as CagriSema, IcoSema, or Semaglutide with other medicines like finerenone or dapagliflozin.^[1][4] In these studies, Semaglutide is being tested as part of a broader treatment strategy rather than alone.^[1]

What these trials may help answer

Together, the studies ask where Semaglutide may help most, which patient groups may benefit, and which outcomes improve first.^[2] They also compare different doses, different formulations, and different combinations with other treatments.^[4][7]

The data show that research on Semaglutide is broad and still ongoing, with many authorised trials and several completed studies already available.^[2] The overall focus is on real clinical results that matter to patients, such as blood sugar, weight, kidney health, heart outcomes, and quality of life.^[6][8]

Table of Contents

• What is Risperidone?
• Conditions Treated with Risperidone
• Forms and Administration of Risperidone
• Effectiveness of Risperidone
• Side Effects and Safety Considerations
• Ongoing Research and Clinical Trials

What is Risperidone?

Risperidone is an antipsychotic medication used to treat various mental health conditions^[1]. It belongs to a class of drugs known as atypical antipsychotics, which work by affecting certain chemicals in the brain to help control symptoms of mental disorders. Risperidone is also known by its brand names, including Risperdal, Risperdal Consta, and Perseris^[2][3].

Conditions Treated with Risperidone

Risperidone is primarily used to treat the following conditions:

• Schizophrenia: A severe mental disorder characterized by distorted thinking, hallucinations, and impaired emotional responsiveness^[4].
• Bipolar disorder: A condition that causes extreme mood swings, including emotional highs (mania) and lows (depression).
• Autism Spectrum Disorder (ASD): A developmental disorder that affects communication and behavior^[5].
• Cocaine-related disorders: In some cases, risperidone has been studied for its potential in treating cocaine dependence^[6].

Forms and Administration of Risperidone

Risperidone is available in several forms to suit different patient needs:

• Oral tablets: These are taken by mouth, usually once or twice daily^[3].
• Orally disintegrating tablets (ODT): These tablets dissolve quickly in the mouth without needing water, which can be helpful for patients who have difficulty swallowing pills^[3].
• Long-acting injectable (LAI): Also known as Risperdal Consta or Perseris, this form is injected into a muscle every two to four weeks by a healthcare professional^[4][2].

The dosage and form of risperidone prescribed will depend on the condition being treated, the severity of symptoms, and individual patient factors. It’s important to take risperidone exactly as prescribed by your doctor.

Effectiveness of Risperidone

Research has shown that risperidone can be effective in managing symptoms of various mental health conditions:

• Schizophrenia: Studies have demonstrated that risperidone can help reduce symptoms such as hallucinations, delusions, and disorganized thinking. It may also improve social functioning and quality of life for patients with schizophrenia^[7].
• Autism Spectrum Disorder: Risperidone has been found to help manage irritability, aggression, and self-injurious behaviors in some individuals with ASD^[5].
• Bipolar Disorder: The medication can help stabilize mood and reduce manic episodes in people with bipolar disorder.

Effectiveness is often measured using various scales and assessments, such as the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, or the Clinical Global Impression (CGI) scale for overall improvement^[4][7].

Side Effects and Safety Considerations

Like all medications, risperidone can cause side effects. Common side effects may include:

• Weight gain
• Drowsiness or fatigue
• Increased appetite
• Dizziness
• Constipation
• Dry mouth
• Nausea

More serious side effects, though less common, can include:

• Extrapyramidal symptoms: These are movement disorders that can cause restlessness, muscle stiffness, or involuntary movements^[2].
• Metabolic changes: Risperidone may affect blood sugar levels, cholesterol, and triglycerides.
• Increased prolactin levels: This can lead to breast enlargement, irregular menstrual cycles in women, or erectile dysfunction in men.
• Tardive dyskinesia: A potentially irreversible condition causing involuntary movements, particularly of the face and mouth.

It’s crucial to discuss any side effects with your healthcare provider. They can help manage side effects or adjust your treatment if necessary. Regular check-ups and monitoring are important while taking risperidone^[2].

Ongoing Research and Clinical Trials

Researchers continue to study risperidone to better understand its effects and explore new potential uses:

• Comparison with other medications: Studies are comparing risperidone to other antipsychotics, such as aripiprazole, to determine their relative effectiveness and side effect profiles^[5].
• Long-acting injectable formulations: Research is ongoing to develop and improve long-acting injectable forms of risperidone, which could help with medication adherence^[2].
• Effects on oxidative stress: Some studies are investigating how risperidone affects oxidative stress in patients with autism spectrum disorder, which could provide insights into its mechanism of action^[5].
• Use in substance abuse disorders: Researchers are exploring the potential of risperidone in treating substance-related disorders, such as cocaine dependence^[6].

These ongoing studies aim to improve our understanding of risperidone and potentially expand its therapeutic uses. As with any medication, it’s important to stay informed about the latest research and discuss any questions or concerns with your healthcare provider.

Table of Contents

• Introduction
• What is Rituximab?
• Conditions Treated with Rituximab
• How Rituximab Works
• How Rituximab is Administered
• Combination Therapies with Rituximab
• Efficacy of Rituximab
• Potential Side Effects
• Ongoing Research
• Frequently Asked Questions
• Glossary

Introduction

Rituximab is an innovative medication that has shown promising results in treating various autoimmune diseases and certain types of cancer. This article will provide a comprehensive overview of Rituximab, its uses, and what patients should know about this treatment.^[1][2]

What is Rituximab?

Rituximab is a type of drug known as a monoclonal antibody. It is specifically designed to target a protein called CD20, which is found on the surface of certain white blood cells called B cells. Rituximab is also known by its brand names MabThera and Rituxan.^[3]

Conditions Treated with Rituximab

Rituximab has been found effective in treating several conditions, including:

• Pemphigus: An autoimmune disease affecting the skin and mucous membranes^[1]
• Non-Hodgkin Lymphoma: A type of cancer that affects the lymphatic system^[3]
• Chronic Lymphocytic Leukemia (CLL): A type of cancer affecting white blood cells^[4]
• Diffuse Large B Cell Lymphoma: An aggressive type of non-Hodgkin lymphoma^[5]
• Burkitt’s Lymphoma: A rare but aggressive form of non-Hodgkin lymphoma^[2]
• Acute Lymphoblastic Leukemia: A type of cancer of the blood and bone marrow^[2]

How Rituximab Works

Rituximab works by targeting and destroying B cells in the body. In autoimmune diseases, these B cells mistakenly attack the body’s own tissues. In certain cancers, these B cells become cancerous and multiply uncontrollably. By eliminating these problematic B cells, Rituximab can help control the disease.^[1]

How Rituximab is Administered

Rituximab is typically administered in one of two ways:

1. Intravenous (IV) infusion: The drug is given directly into a vein over several hours. The dose is usually 375 mg/m² of body surface area.^[2]
2. Subcutaneous (SC) injection: A newer method where the drug is injected under the skin. The standard dose for this method is 1400 mg.^[5]

The treatment schedule can vary depending on the condition being treated and may involve multiple doses over several weeks or months.

Combination Therapies with Rituximab

Rituximab is often used in combination with other treatments to enhance its effectiveness. Some common combinations include:

• Rituximab with corticosteroids for pemphigus^[1]
• Rituximab with chemotherapy drugs like fludarabine and cyclophosphamide for non-Hodgkin lymphoma^[3]
• Rituximab with venetoclax and ibrutinib for chronic lymphocytic leukemia^[4]
• Rituximab with a reduced-intensity chemotherapy regimen (mini-CHOP) for older patients with diffuse large B cell lymphoma^[5]

Efficacy of Rituximab

Clinical trials have shown promising results for Rituximab in various conditions:

• In pemphigus, Rituximab combined with short-term corticosteroid therapy has shown to be highly effective, leading to complete remission in many patients for up to 3 years.^[1]
• For non-Hodgkin lymphoma, Rituximab in combination with chemotherapy has shown improved response rates and disease-free intervals compared to conventional treatments.^[3]
• In chronic lymphocytic leukemia, Rituximab combined with other targeted therapies has shown potential in achieving undetectable minimal residual disease, a sign of deep remission.^[4]

Potential Side Effects

While Rituximab is generally well-tolerated, it can cause some side effects. These may include:

• Infusion-related reactions (during or shortly after receiving the drug)
• Increased risk of infections
• Fatigue
• Nausea
• Headache

Your healthcare provider will monitor you closely for any adverse reactions.^[1]

Ongoing Research

Research on Rituximab is ongoing, with clinical trials exploring its use in various conditions and in combination with other treatments. Some areas of current research include:

• Long-term effects and optimal dosing schedules^[1]
• Combination with newer targeted therapies^[4]
• Use in older patients with aggressive lymphomas^[5]

Frequently Asked Questions

How long does Rituximab treatment last?

The duration of Rituximab treatment can vary depending on the condition being treated and the individual response. Some treatments may involve a few doses over several weeks, while others may continue for months or even years. Your doctor will determine the best treatment plan for your specific situation.

Can Rituximab cure my condition?

While Rituximab has shown to be highly effective in many cases, it’s important to understand that it may not cure the condition in all patients. For some, it can lead to long-term remission, while for others, it may help manage symptoms and slow disease progression. The effectiveness can vary depending on the specific condition and individual factors.

Are there any long-term risks associated with Rituximab?

Long-term studies on Rituximab are still ongoing. While it has been used safely for many years, there are some potential long-term risks to consider, such as an increased risk of certain infections due to its effects on the immune system. Your doctor will discuss these potential risks with you and weigh them against the benefits of treatment.

Summary Table

Glossary

• Monoclonal antibody – A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They can be used alone or to carry drugs, toxins, or radioactive substances directly to cancer cells.
• CD20 – A protein found on the surface of B cells, which are a type of white blood cell.
• Autoimmune disease – A condition in which the body’s immune system attacks its own tissues.
• Lymphoma – A type of cancer that begins in cells of the lymph system.
• Leukemia – A type of cancer of the blood or bone marrow.
• Remission – A decrease in or disappearance of signs and symptoms of cancer.

Trial Sources

• [1]: https://clinicaltrials.gov/study/NCT03790293
• [2]: https://clinicaltrials.gov/study/NCT00388193
• [3]: https://clinicaltrials.gov/study/NCT01124526
• [4]: https://clinicaltrials.gov/study/NCT04758975
• [5]: https://clinicaltrials.gov/study/NCT02128061

Table of Contents

• Trial overview
• Study design and treatment groups
• Who participated
• What the trial measured
• Why this study matters

Trial overview

The trial titled Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine studied people with depression.^[1] It was an interventional Phase 3 study with 100 enrolled participants and a completed status.^[1]

The study looked at two goals: reducing cognitive side-effects after ECT and improving the ability to predict who would respond to ECT.^[1] ECT means electroconvulsive therapy, a treatment used in severe depression.^[1]

Study design and treatment groups

The trial compared RIVASTIGMINE with placebo using transdermal use, which means the treatment was given through the skin with an adhesive plaster.^[1] The source lists two active doses, 9.5 mg and 4.6 mg, and matching placebo plasters that contained 0 mg of rivastigmin.^[1]

This design helped researchers compare changes in thinking and memory between the RIVASTIGMINE group and the placebo group.^[1]

Who participated

The target population was people with depression.^[1] The source does not provide more detailed entry rules, such as age limits, severity rules, or other medical conditions required for participation.

Because the study focused on ECT, the participants were people for whom ECT was being considered or used as part of care in the research setting.^[1]

What the trial measured

The main outcome was whether there was no change in the RIVASTIGMINE group on cognitive and memory-related measures, compared with an effect in the placebo group.^[1] In simple terms, the researchers wanted to see if RIVASTIGMINE could prevent or reduce worsening in thinking and memory after ECT.^[1]

The trial also measured whether a classification algorithm could accurately predict ECT response and side-effects at a statistically significant level.^[1] A classification algorithm is a rule-based or computer-based method that sorts people into groups, such as likely responder or non-responder.^[1]

Another part of the study used EEG, which is a test that records brain activity, to help build the prediction method for ECT response.^[1]

Why this study matters

The study aimed to improve the acceptability and tolerability of ECT by reducing its cognitive side-effects.^[1] Better memory and thinking outcomes could make ECT easier to use for people with chronic severe depression.^[1]

The researchers also wanted to avoid giving ECT to people who are unlikely to benefit, because this could expose them to risks without enough chance of improvement.^[1] In this way, the trial combined a treatment question with a prediction question: can RIVASTIGMINE help after ECT, and can EEG plus clinical data better forecast ECT results?^[1]

Table of Contents

• What is Rifaximin?
• Conditions Treated with Rifaximin
• How Rifaximin Works
• Dosage and Administration
• Ongoing Research and Potential New Uses
• Potential Side Effects

What is Rifaximin?

Rifaximin is an antibiotic medication that is primarily used to treat various gastrointestinal conditions. It is also known by its brand name Xifaxan^[1]. Unlike many other antibiotics, rifaximin is considered a non-systemic antibiotic, which means it primarily acts within the gut and is not significantly absorbed into the bloodstream^[2]. This unique characteristic allows it to target bacteria in the intestines while minimizing potential side effects in other parts of the body.

Conditions Treated with Rifaximin

Rifaximin is used to treat several gastrointestinal conditions, including:

• Irritable Bowel Syndrome (IBS): Particularly for diarrhea-predominant IBS (IBS-D) and mixed IBS (IBS-M)^[3].
• Hepatic Encephalopathy: A brain condition that occurs when the liver is unable to remove toxins from the blood^[4].
• Bacterial Vaginosis: An infection caused by an imbalance of bacteria in the vagina^[5].
• Small Intestinal Bacterial Overgrowth (SIBO): A condition where excessive bacteria grow in the small intestine^[3].
• Cirrhosis: A late stage of scarring of the liver^[6].

How Rifaximin Works

Rifaximin works by reducing the number of harmful bacteria in the intestines. It does this by inhibiting bacterial protein synthesis, which prevents the bacteria from growing and multiplying^[2]. This action can help alleviate symptoms associated with various gastrointestinal conditions, such as diarrhea, abdominal pain, and bloating.

In the case of hepatic encephalopathy, rifaximin helps by reducing the production of ammonia in the gut. Ammonia is a toxic substance that can build up in the blood when the liver is not functioning properly, leading to brain dysfunction^[4].

Dosage and Administration

The dosage and duration of rifaximin treatment can vary depending on the condition being treated. Some common dosages include:

• For IBS: 550 mg taken orally three times a day for 14 days^[3].
• For hepatic encephalopathy: 550 mg taken orally twice a day^[4].
• For bacterial vaginosis: Dosages may vary, but one study investigated 25 mg and 100 mg vaginal tablets administered once a day for 5 days^[5].

It’s important to note that rifaximin should always be taken as prescribed by your healthcare provider.

Ongoing Research and Potential New Uses

Researchers are continuously exploring new potential uses for rifaximin. Some areas of ongoing research include:

• Primary Sclerosing Cholangitis (PSC): A study is investigating the potential benefits of rifaximin in patients with this chronic liver disease^[7].
• Sickle Cell Disease: Researchers are studying whether rifaximin can modify the disease course in patients with sickle cell disease by altering the gut microbiome^[8].
• Monoclonal Gammopathy: A pilot study is evaluating the effects of rifaximin on patients with this blood disorder characterized by abnormal protein production^[9].
• Sleep Disorders in Hepatic Encephalopathy: Researchers are investigating whether rifaximin can improve sleep quality in patients with hepatic encephalopathy^[10].

Potential Side Effects

While rifaximin is generally well-tolerated due to its limited systemic absorption, some patients may experience side effects. Common side effects may include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Headache

It’s important to report any unusual or severe side effects to your healthcare provider^[8].

Table of Contents

• What is Radotinib Dihydrochloride?
• Parkinson’s Disease: An Overview
• Clinical Trial Information
• Study Objectives
• Eligibility Criteria
• Safety and Side Effects
• Potential Benefits

What is Radotinib Dihydrochloride?

Radotinib Dihydrochloride, also known as Radotinib hydrochloride, is a medication currently being studied for the treatment of Parkinson’s disease (PD)^[1]. It is manufactured by IL-YANG PHARM CO. LTD. and is being investigated as a potential new therapy for people with Parkinson’s disease. The drug is administered orally in the form of capsules^[2].

Parkinson’s Disease: An Overview

Parkinson’s disease is a progressive neurological disorder that affects movement, balance, and coordination. It occurs when certain nerve cells (neurons) in the brain gradually break down or die. These neurons produce a chemical called dopamine, which helps control movement and coordination. As Parkinson’s disease progresses, the amount of dopamine produced in the brain decreases, causing movement symptoms to worsen over time^[3].

Clinical Trial Information

A clinical trial is currently underway to evaluate Radotinib Dihydrochloride as a potential treatment for Parkinson’s disease. This study is a Phase II trial, which means it is designed to assess the drug’s safety, effectiveness, and side effects in a larger group of patients^[4]. The trial is described as a “randomized double-blind placebo-controlled multicentre study,” which ensures that the results are as unbiased and reliable as possible.

Key features of the trial include:

• Testing different doses of Radotinib (50, 100, 150, and 200 mg)
• Treatment duration of 6 months
• Comparison with a placebo (an inactive substance)
• Involvement of multiple research centers

Study Objectives

The clinical trial has several objectives to evaluate Radotinib’s potential as a treatment for Parkinson’s disease^[5]:

1. Primary objective: To assess the safety and tolerability of Radotinib compared to placebo in people with Parkinson’s disease.
2. Secondary objectives:
   • To study how Radotinib is processed by the body (pharmacokinetics) at different doses.
   • To evaluate the effectiveness of Radotinib in reducing motor symptoms of Parkinson’s disease, as measured by a standardized scale called the MDS-UPDRS.
   • To determine if Radotinib can delay the need for traditional dopamine-replacement medications.
   • To assess the impact of Radotinib on patients’ quality of life.
   • To evaluate the overall clinical improvement as perceived by patients.

Eligibility Criteria

The clinical trial has specific criteria for participants to ensure the safety of the study and the reliability of the results. Some key eligibility criteria include^[6]:

• Age: 40 to 80 years old
• Diagnosed with “Clinically Probable Parkinson’s disease” within the last three years
• Positive DAT-scan (a special brain imaging test that helps confirm Parkinson’s disease)
• Early-stage Parkinson’s disease (Hoehn & Yahr stage ≤ 2.5)
• No previous treatment for Parkinson’s disease
• Absence of other neurological conditions that could explain symptoms

There are also several exclusion criteria, such as certain medical conditions, medications, or circumstances that would prevent someone from participating in the study.

Safety and Side Effects

As this is a Phase II clinical trial, one of the main objectives is to evaluate the safety and tolerability of Radotinib Dihydrochloride^[7]. The researchers will be closely monitoring for any adverse events (side effects) throughout the study. They will also be tracking vital signs, performing ECGs (heart tests), conducting laboratory tests, and carrying out physical examinations to ensure the safety of the participants.

It’s important to note that as this is an investigational drug, not all potential side effects may be known at this time. Participants in the study will be closely monitored and any adverse events will be promptly addressed.

Potential Benefits

While it’s too early to know for certain, Radotinib Dihydrochloride may offer several potential benefits for people with Parkinson’s disease^[8]:

• Possible improvement in motor symptoms of Parkinson’s disease
• Potential delay in the need for traditional Parkinson’s medications
• Possible improvement in quality of life
• Contribution to the advancement of Parkinson’s disease research

It’s important to remember that as this is a clinical trial, these potential benefits are not guaranteed and more research is needed to confirm the effectiveness of Radotinib in treating Parkinson’s disease.

Table of Contents

• What is Quetiapine?
• Conditions Treated with Quetiapine
• How Quetiapine Works
• Forms and Dosages
• Side Effects and Tolerability
• Use in Special Populations
• Ongoing Research and Future Applications

What is Quetiapine?

Quetiapine, also known by its brand name Seroquel^[1], is a medication classified as an atypical antipsychotic. It is widely used in the treatment of various mental health conditions. Quetiapine comes in two forms: immediate release (IR) and extended release (XR)^[3]. The extended-release version is sometimes referred to as Seroquel XR^[3].

Conditions Treated with Quetiapine

Quetiapine is used to treat several mental health conditions, including:

• Schizophrenia: A severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior^[2].
• Bipolar Disorder: A condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression)^[6].
• Major Depressive Disorder: A mood disorder causing a persistent feeling of sadness and loss of interest^[5].
• Generalized Anxiety Disorder: A condition characterized by persistent and excessive worry about various aspects of life^[5].

Research is also being conducted to explore its potential use in treating other conditions such as cannabis dependence^[8] and postpartum depression with psychotic symptoms^[10].

How Quetiapine Works

Quetiapine affects multiple neurotransmitter receptors in the brain. It primarily works on:

• Serotonin receptors: Helping to regulate mood and anxiety
• Dopamine receptors: Influencing thought processes and behavior
• Histamine receptors: Contributing to its sedative effects
• Adrenergic receptors: Affecting various bodily functions^[11]

By interacting with these receptors, quetiapine helps to balance the brain chemistry, potentially reducing symptoms of various mental health conditions.

Forms and Dosages

Quetiapine is available in tablet form and comes in various strengths, typically ranging from 25 mg to 300 mg^[1][2]. The dosage prescribed depends on the condition being treated, the severity of symptoms, and individual patient factors. It’s important to note that dosages should only be adjusted under the guidance of a healthcare professional.

For example, in some studies:

• Doses of 600 mg to 1200 mg per day were used for treatment-resistant schizophrenia^[2].
• A target dose of 150 mg per day was used for treating depression and anxiety^[5].
• Doses ranging from 25 mg to 300 mg twice daily were used in various studies^[8][10].

Side Effects and Tolerability

Like all medications, quetiapine can cause side effects. Common side effects may include:

• Drowsiness or sedation
• Dizziness
• Dry mouth
• Weight gain
• Changes in blood sugar levels

The tolerability of quetiapine can vary among individuals. Some studies have specifically looked at the tolerability of different formulations and dosing schedules^[3]. It’s important to discuss any side effects with your healthcare provider.

Use in Special Populations

Quetiapine use in special populations, such as pregnant women and children, is an area of ongoing research:

• Pregnancy: Studies are being conducted to understand how pregnancy affects the metabolism of quetiapine and to determine appropriate dosing during pregnancy and postpartum^[6].
• Children and Adolescents: Some research has explored the use of quetiapine in preschool children with bipolar disorder, but its use in pediatric populations requires careful consideration and monitoring^[11].

Ongoing Research and Future Applications

Researchers continue to explore new potential uses for quetiapine and ways to optimize its use:

• Its potential effectiveness in treating cannabis dependence is being studied^[8].
• Research is being conducted on its use in treating postpartum depression with psychotic symptoms^[10].
• Studies are investigating how bariatric surgery might affect the way the body processes quetiapine^[4].

As with any medication, it’s crucial to use quetiapine only as prescribed by a healthcare professional. Regular check-ups and open communication with your doctor about any concerns or side effects are essential for safe and effective treatment.

Table of Contents

• What is Psilocybin?
• Conditions Treated with Psilocybin
• How Psilocybin Works
• How Psilocybin is Administered
• Effects of Psilocybin
• Ongoing Research
• Safety Considerations

What is Psilocybin?

Psilocybin is a naturally occurring psychoactive compound found in certain species of mushrooms, commonly known as “magic mushrooms”. It is being studied as a potential treatment for various mental health conditions. Psilocybin is also known by other names such as psilocybine, psilocibin, and benzodiazepine^[1].

In medical research, psilocybin is typically synthesized in a laboratory to ensure purity and precise dosing. It works by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor, which can lead to altered states of consciousness and potential therapeutic effects^[2].

Conditions Treated with Psilocybin

Research is exploring the use of psilocybin for treating several mental health conditions:

• Major Depressive Disorder (MDD): Studies are investigating psilocybin’s potential to rapidly reduce depressive symptoms, especially in patients with cancer-related depression^[3].
• Anxiety Disorders: Psilocybin is being studied for its effects on reducing anxiety, particularly in patients with life-threatening illnesses^[2].
• Opioid Use Disorder (OUD): Researchers are exploring whether psilocybin can help individuals overcome opioid addiction when used alongside standard treatments like buprenorphine^[4].
• Basic Science Research: Some studies are investigating how psilocybin affects brain function and consciousness in healthy volunteers^[2].

How Psilocybin Works

Psilocybin is thought to work by:

• Altering brain connectivity: It may change how different parts of the brain communicate with each other, potentially allowing for new perspectives and breaking negative thought patterns^[2].
• Enhancing neuroplasticity: Psilocybin might increase the brain’s ability to form new connections and adapt, which could help in treating various mental health conditions^[5].
• Affecting serotonin receptors: By interacting with serotonin receptors, particularly 5-HT2A receptors, psilocybin can influence mood, perception, and cognition^[2].

How Psilocybin is Administered

In clinical trials, psilocybin is typically administered in the following ways:

• Oral capsules: Most studies use oral capsules containing precise doses of psilocybin, ranging from very low doses (1 mg) to higher doses (25-30 mg)^[3][4].
• Intravenous (IV) infusion: Some studies are exploring the use of IV psilocybin, particularly for investigating its effects on sleep and consciousness^[6].

Psilocybin is usually given in controlled settings under medical supervision, often with psychological support before, during, and after the experience^[4].

Effects of Psilocybin

The effects of psilocybin can vary depending on the dose and individual factors. Some potential effects include:

• Altered state of consciousness: This may include changes in perception, thought patterns, and sense of self^[2].
• Emotional breakthroughs: Some people report experiencing intense emotions or gaining new insights into personal issues^[6].
• Changes in mood: Psilocybin may lead to improvements in mood and reductions in anxiety and depression symptoms^[3].
• Mystical-type experiences: Some individuals report having profound, spiritually significant experiences^[6].

It’s important to note that these effects can be intense and may be challenging for some individuals. This is why psilocybin is administered in controlled settings in clinical trials^[4].

Ongoing Research

Several clinical trials are currently investigating various aspects of psilocybin treatment:

• Dosing strategies: Researchers are comparing different doses of psilocybin to determine the most effective and safe dosing regimens^[3][4].
• Combination with other treatments: Some studies are looking at how psilocybin works when combined with other therapies, such as buprenorphine for opioid use disorder^[4].
• Long-term effects: Researchers are investigating how long the potential benefits of psilocybin treatment may last^[3].
• Brain imaging studies: Some trials are using techniques like fMRI (functional magnetic resonance imaging) to understand how psilocybin affects brain activity and connectivity^[2].

Safety Considerations

While psilocybin shows promise in clinical trials, it’s important to understand that:

• Psilocybin is still considered an experimental treatment and is not yet approved for general medical use.
• The use of psilocybin outside of controlled clinical settings can be dangerous and is illegal in many countries.
• Psilocybin can interact with other medications and may not be suitable for people with certain mental health conditions or medical histories.
• The long-term effects and potential risks of psilocybin treatment are still being studied^[4][6].

Always consult with a healthcare professional before considering any new treatment, including participation in clinical trials involving psilocybin.